

# EAU Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and CIS)

M. Babjuk (Chair), M. Burger (Vice-Chair), E. Compérat,  
P. Gontero, A.H. Mostafid, J. Palou, B.W.G. van Rhijn,  
M. Rouprêt, S.F. Shariat, R. Sylvester, R. Zigeuner  
Guidelines Associates: O. Capoun, D. Cohen,  
V. Hernández, V. Soukup

# TABLE OF CONTENTS

# PAGE

1.	INTRODUCTION	5
1.1	Aim and scope	5
1.2	Panel composition	5
1.3	Available publications	5
1.4	Publication history and summary of changes	5
1.4.1	Publication history	5
1.4.2	Summary of changes	5
2.	METHODS	6
2.1	Data Identification	6
2.2	Review	6
2.3	Future goals	6
3.	EPIDEMIOLOGY, AETIOLOGY AND PATHOLOGY	7
3.1	Epidemiology	7
3.2	Aetiology	7
3.3	Pathology	7
3.4	Summary of evidence for epidemiology, aetiology and pathology	7
4.	STAGING AND CLASSIFICATION SYSTEMS	8
4.1	Definition of non-muscle-invasive bladder cancer	8
4.2	Tumour, Node, Metastasis Classification (TNM)	8
4.3	T1 subclassification	8
4.4	Histological grading of non-muscle-invasive bladder urothelial carcinomas	8
4.5	Carcinoma <i>in situ</i> and its classification	9
4.6	Inter- and intra-observer variability in staging and grading	10
4.7	Further pathology parameters	10
4.8	Summary of evidence and guidelines for bladder cancer classification	10
5.	DIAGNOSIS	10
5.1	Patient history	10
5.2	Signs and symptoms	10
5.3	Physical examination	10
5.4	Imaging	10
5.4.1	Computed tomography urography and intravenous urography	10
5.4.2	Ultrasound (US)	11
5.5	Urinary cytology	11
5.6	Urinary molecular marker tests	11
5.7	Potential application of urinary cytology and markers	12
5.7.1	Screening of the population at risk of bladder cancer	12
5.7.2	Exploration of patients after haematuria or other symptoms suggestive of bladder cancer (primary detection)	12
5.7.3	Surveillance of non-muscle-invasive bladder cancer	12
5.7.3.1	Follow-up of high-risk non-muscle-invasive bladder cancer	12
5.7.3.2	Follow-up of low/intermediate-risk non-muscle-invasive bladder cancer	12
5.8	Cystoscopy	12
5.9	Summary of evidence and guidelines for the primary assessment of non-muscle-invasive bladder cancer	13
5.10	Transurethral resection of TaT1 bladder tumours	13
5.10.1	Strategy of the procedure	13
5.10.2	Surgical and technical aspects of tumour resection	13
5.10.2.1	Surgical strategy of resection (resection in fractions, <i>en-bloc</i> resection)	13
5.10.2.2	Evaluation of resection quality	14
5.10.2.3	Monopolar and bipolar resection	14

5.10.2.4	Office-based fulguration and laser vaporisation	14
5.10.2.5	Resection of small papillary bladder tumours at the time of transurethral resection of the prostate (TURP)	14
5.10.3	Bladder and prostatic urethral biopsies	14
5.11	New methods of tumour visualisation	14
5.11.1	Photodynamic diagnosis (fluorescence cystoscopy)	14
5.11.2	Narrow-band imaging	15
5.12	Second resection	15
5.13	Pathology report	15
5.14	Summary of evidence and guidelines for transurethral resection of the bladder, biopsies and pathology report	16
6.	PREDICTING DISEASE RECURRENCE AND PROGRESSION	17
6.1	TaT1 tumours	17
6.2	Carcinoma <i>in situ</i>	19
6.3	Patient stratification into risk groups	19
6.4	Subgroup of highest-risk tumours	19
6.5	Summary of evidence and guidelines for stratification of non-muscle-invasive bladder cancer	20
7.	DISEASE MANAGEMENT	20
7.1	Counselling of smoking cessation	20
7.2	Adjuvant treatment	20
7.2.1	Intravesical chemotherapy	20
7.2.1.1	A single, immediate, post-operative intravesical instillation of chemotherapy	20
7.2.1.2	Additional adjuvant intravesical chemotherapy instillations	21
7.2.1.3	Options for improving efficacy of intravesical chemotherapy	21
7.2.1.3.1	Adjustment of pH, duration of instillation, and drug concentration	21
7.2.1.3.2	Device-assisted intravesical chemotherapy	21
7.2.1.4	Summary of evidence - intravesical chemotherapy	22
7.2.2	Intravesical bacillus Calmette-Guérin (BCG) immunotherapy	22
7.2.2.1	Efficacy of BCG	22
7.2.2.2	BCG strain	22
7.2.2.3	BCG toxicity	23
7.2.2.4	Optimal BCG schedule	24
7.2.2.5	Optimal dose of BCG	24
7.2.2.6	Indications for BCG	24
7.2.2.7	Summary of evidence - BCG treatment	24
7.2.3	Combination therapy	25
7.2.4	Specific aspects of treatment of Carcinoma <i>in situ</i>	25
7.2.4.1	Treatment strategy	25
7.2.4.2	Cohort studies on intravesical BCG or chemotherapy	25
7.2.4.3	Prospective randomised trials on intravesical BCG or chemotherapy	25
7.2.4.4	Treatment of CIS in prostatic urethra and upper urinary tract	25
7.2.4.5	Summary of evidence – treatment of carcinoma <i>in situ</i>	25
7.3	Treatment of failure of intravesical therapy	27
7.3.1	Failure of intravesical chemotherapy	27
7.3.2	Recurrence and failure after intravesical bacillus Calmette-Guérin (BCG) immunotherapy	27
7.3.3	Treatment of BCG failure and recurrences after BCG	27
7.3.4	Summary of evidence - treatment failure of intravesical therapy	27
7.4	Radical cystectomy for NMIBC	28
7.5	Guidelines for adjuvant therapy in TaT1 tumours and for therapy of carcinoma <i>in situ</i>	29
7.6	Treatment recommendations in TaT1 tumours and carcinoma <i>in situ</i> according to risk stratification	30
7.7	Treatment options for bacillus Calmette-Guérin (BCG) failure and recurrences after BCG	30

8.	FOLLOW-UP OF PATIENTS WITH NMIBC	30
8.1	Summary of evidence and guidelines for follow-up of patients after transurethral resection of the bladder for non-muscle-invasive bladder cancer	31
9.	REFERENCES	32
10.	CONFLICT OF INTEREST	48
11.	CITATION INFORMATION	48

# 1. INTRODUCTION

## 1.1 Aim and scope

This overview represents the updated European Association of Urology (EAU) Guidelines for Non-muscle-invasive Bladder Cancer (NMIBC), TaT1 and carcinoma *in situ* (CIS). The information presented is limited to urothelial carcinoma, unless specified otherwise. The aim is to provide practical recommendations on the clinical management of NMIBC with a focus on clinical presentation and recommendations.

Separate EAU Guidelines documents are available addressing upper tract urothelial carcinoma (UTUC) [1], muscle-invasive and metastatic bladder cancer (MIBC) [2], and primary urethral carcinoma [3]. It must be emphasised that clinical guidelines present the best evidence available to the experts, but following guideline recommendations will not necessarily result in the best outcome. Guidelines can never replace clinical expertise when making treatment decisions for individual patients, but rather help to focus decisions - also taking personal values and preferences/individual circumstances of patients into account. Guidelines are not mandates and do not purport to be a legal standard of care.

## 1.2 Panel composition

The EAU Guidelines Panel on NMIBC consists of an international multidisciplinary group of clinicians, including urologists, uro-oncologists, a pathologist and a statistician. Members of this Panel have been selected based on their expertise and to represent the professionals treating patients suspected of suffering from bladder cancer. All experts involved in the production of this document have submitted potential conflict of interest statements which can be viewed on the EAU website Uroweb: <https://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/>.

## 1.3 Available publications

A quick reference document (Pocket guidelines) is available, both in print and as an app for iOS and Android devices. These are abridged versions which may require consultation together with the full text version. Several scientific publications are available, the latest publication dating to 2016 [4], as are a number of translations of all versions of the EAU NMIBC Guidelines. All documents are accessible through the EAU website Uroweb: <https://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/>.

## 1.4 Publication history and summary of changes

### 1.4.1 Publication history

The EAU Guidelines on Bladder Cancer were first published in 2000. This 2018 NMIBC Guidelines document presents a limited update of the 2017 publication.

### 1.4.2 Summary of changes

Additional data has been included in sections:

- 4.4 4.4 - Histological grading of non-muscle-invasive bladder urothelial carcinomas
- 5.11.1 - Photodynamic diagnosis (fluorescence cystoscopy);
- 5.12 - Second resection;
- 7.2.1.3.2 - Device-assisted intravesical chemotherapy.

New recommendations have been added to:

- Section 5.9 - Summary of evidence and guidelines for the primary assessment of non-muscle-invasive bladder cancer

Recommendations	Strength rating
In men, use flexible cystoscope, if available.	Strong
Describe all macroscopic features of the tumour (site, size, number and appearance) and mucosal abnormalities during cystoscopy. Use a bladder diagram (Figure 5.1).	Strong
Use the Paris system for cytology reporting.	Strong

- Section 5.14 - Summary of evidence and guidelines for transurethral resection of the bladder, biopsies and pathology report

Recommendations	Strength rating
<b>Performance of individual steps</b>	
Use methods to improve tumour visualization (FC, NBI) during TURB, if available.	Weak

## 2. METHODS

### 2.1 Data Identification

For the 2018 NMIBC Guidelines, new and relevant evidence has been identified, collated and appraised through a structured assessment of the literature.

A broad and comprehensive scoping exercise covering all areas of the NMIBC Guidelines was performed. Excluded from the search were basic research studies, case series, reports and editorial comments. Only articles published in the English language, addressing adults, were included. The search was restricted to articles published between April 22<sup>nd</sup> 2016 and May 24<sup>th</sup> 2017. Databases covered by the search included Pubmed, Ovid, EMBASE and the Cochrane Central Register of Controlled Trials and the Cochrane Database of Systematic Reviews. After deduplication, a total of 2,631 unique records were identified, retrieved and screened for relevance.

A total of 35 new papers were added to the NMIBC 2018 Guidelines publication. A detailed search strategy is available on line: <https://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/?type=appendices-publications>.

For Chapters 3-6 (Epidemiology, Aetiology and Pathology, Staging and Classification systems, Diagnosis, Predicting disease recurrence and progression) references used in this text are assessed according to their level of evidence (LE) based on the 2009 Oxford Centre for Evidence-Based Medicine (OCEBM) Levels of Evidence [5]. For the Disease Management and Follow-up chapters (Chapters 7 and 8) a system modified from the 2009 CEBM levels of evidence is being used [5].

For the 2018 edition of the EAU Guidelines the Guidelines Office have transitioned to a modified GRADE methodology across all 20 guidelines [6, 7]. For each recommendation within the guidelines there is an accompanying online strength rating form which addresses a number of key elements namely:

1. the overall quality of the evidence which exists for the recommendation;
2. the magnitude of the effect (individual or combined effects);
3. the certainty of the results (precision, consistency, heterogeneity and other statistical or study related factors);
4. the balance between desirable and undesirable outcomes;
5. the impact of patient values and preferences on the intervention;
6. the certainty of those patient values and preferences.

These key elements are the basis which panels use to define the strength rating of each recommendation. The strength of each recommendation is represented by the words 'strong' or 'weak' [6, 7]. The strength of each recommendation is determined by the balance between desirable and undesirable consequences of alternative management strategies, the quality of the evidence (including certainty of estimates), and nature and variability of patient values and preferences. The strength rating forms will be available online.

Additional information can be found in the general Methodology section of this print, and online at the EAU website; <http://www.uroweb.org/guideline/>.

A list of associations endorsing the EAU Guidelines can also be viewed online at the above address.

### 2.2 Review

Publications of systematic reviews were peer reviewed prior to publication [8]. Chapter 7, Disease Management was peer reviewed prior to publication in 2016. All other chapters of the MIBC Guidelines were peer-reviewed in 2015.

### 2.3 Future goals

The results of ongoing reviews will be included in the 2019 update of the NMIBC Guidelines. These reviews are performed using standard Cochrane systematic review methodology; <http://www.cochranelibrary.com/about/about-cochrane-systematic-reviews.html>.

Ongoing projects:

- Individual Patient Data Prognostic Study on WHO 1973 & 2004 Grade and EORTC 2006 risk score in primary TaT1 Bladder Cancer;
- Systematic Review on lymphovascular invasion (LVI) and histology variants.

## 3. EPIDEMIOLOGY, AETIOLOGY AND PATHOLOGY

### 3.1 Epidemiology

Bladder cancer (BC) is the seventh most commonly diagnosed cancer in the male population worldwide, while it drops to eleventh when both genders are considered [9]. The worldwide age-standardised incidence rate (per 100,000 person/years) is 9.0 for men and 2.2 for women [9]. In the European Union the age-standardised incidence rate is 19.1 for men and 4.0 for women [9]. In Europe, the highest age-standardised incidence rate has been reported in Belgium (31 in men and 6.2 in women) and the lowest in Finland (18.1 in men and 4.3 in women) [9].

Worldwide, the BC age-standardised mortality rate (per 100,000 person/years) was 3.2 for men vs. 0.9 for women in 2012 [9]. Bladder cancer incidence and mortality rates vary across countries due to differences in risk factors, detection and diagnostic practices, and availability of treatments. The variations are, however, partly caused by the different methodologies used and the quality of data collection [10]. The incidence and mortality of BC has decreased in some registries, possibly reflecting the decreased impact of causative agents [11].

Approximately 75% of patients with BC present with a disease confined to the mucosa (stage Ta, CIS) or submucosa (stage T1); in younger patients (< 40) this percentage is even higher [12]. Patients with TaT1 and CIS have a high prevalence due to long-term survival in many cases and lower risk of cancer-specific mortality compared to T2-4 tumours [9, 10].

### 3.2 Aetiology

Tobacco smoking is the most important risk factor for BC, accounting for approximately 50% of cases [10, 11, 13, 14] (LE: 3). Tobacco smoke contains aromatic amines and polycyclic aromatic hydrocarbons, which are renally excreted.

Occupational exposure to aromatic amines, polycyclic aromatic hydrocarbons and chlorinated hydrocarbons is the second most important risk factor for BC, accounting for about 10% of all cases. This type of occupational exposure occurs mainly in industrial plants, which process paint, dye, metal and petroleum products [10, 11, 15, 16]. In developed industrial settings, these risks have been reduced by work-safety guidelines, therefore, chemical workers no longer have a higher incidence of BC compared to the general population [10, 15, 16].

While family history seems to have little impact [17] and, to date, no overt significance of any genetic variation for BC has been shown, genetic predisposition has an influence on the incidence of BC via its impact on susceptibility to other risk factors [10, 18-22].

Although the impact of drinking habits is uncertain, the chlorination of drinking water and subsequent levels of trihalomethanes are potentially carcinogenic, also exposure to arsenic in drinking water increases risk [10, 23] (LE: 3). The association between personal hair dye use and risk remains uncertain; an increased risk has been suggested in users of permanent hair dyes with a slow NAT2 acetylation phenotype [10]. Dietary habits seem to have little impact [24-27].

Exposure to ionizing radiation is connected with increased risk; weak association was also suggested for cyclophosphamide and pioglitazone [10, 23, 28] (LE: 3). Schistosomiasis, a chronic endemic cystitis based on recurrent infection with a parasitic trematode, is also a cause of BC [10] (LE: 3).

### 3.3 Pathology

The information presented in this text is limited to urothelial carcinoma, unless otherwise specified.

### 3.4 Summary of evidence for epidemiology, aetiology and pathology

Summary of evidence	LE
Worldwide, bladder cancer is the eleventh most commonly diagnosed cancer.	2a
Several risk factors connected with the risk of bladder cancer diagnosis have been identified.	3

## 4. STAGING AND CLASSIFICATION SYSTEMS

### 4.1 Definition of non-muscle-invasive bladder cancer

Papillary tumours confined to the mucosa and invading the lamina propria are classified as stage Ta and T1, respectively, according to the Tumour, Node, Metastasis (TNM) classification system [29]. Flat, high-grade tumours that are confined to the mucosa are classified as CIS (Tis). These tumours can be treated by transurethral resection of the bladder (TURB), eventually in combination with intravesical instillations and are therefore grouped under the heading of NMIBC for therapeutic purposes. However, molecular biology techniques and clinical experience have demonstrated the highly malignant potential of CIS and T1 lesions as compared to Ta lesions. The terms “NMIBC” and “superficial BC” are therefore suboptimal descriptions.

### 4.2 Tumour, Node, Metastasis Classification (TNM)

The 2009 TNM classification approved by the Union International Contre le Cancer (UICC) was updated in 2016 (8<sup>th</sup> Edn.), but with no changes in relation to bladder tumours (Table 4.1) [29].

**Table 4.1: 2017 TNM classification of urinary bladder cancer**

<b>T - Primary tumour</b>	
TX	Primary tumour cannot be assessed
T0	No evidence of primary tumour
Ta	Non-invasive papillary carcinoma
Tis	Carcinoma <i>in situ</i> : ‘flat tumour’
T1	Tumour invades subepithelial connective tissue
T2	Tumour invades muscle
T2a	Tumour invades superficial muscle (inner half)
T2b	Tumour invades deep muscle (outer half)
T3	Tumour invades perivesical tissue
T3a	Microscopically
T3b	Macroscopically (extravesical mass)
T4	Tumour invades any of the following: prostate stroma, seminal vesicles, uterus, vagina, pelvic wall, abdominal wall
T4a	Tumour invades prostate stroma, seminal vesicles, uterus or vagina
T4b	Tumour invades pelvic wall or abdominal wall
<b>N – Regional lymph nodes</b>	
NX	Regional lymph nodes cannot be assessed
N0	No regional lymph node metastasis
N1	Metastasis in a single lymph node in the true pelvis (hypogastric, obturator, external iliac, or presacral)
N2	Metastasis in multiple regional lymph nodes in the true pelvis (hypogastric, obturator, external iliac, or presacral)
N3	Metastasis in common iliac lymph node(s)
<b>M - Distant metastasis</b>	
M0	No distant metastasis
M1a	Non-regional lymph nodes
M1b	Other distant metastases

### 4.3 T1 subclassification

The depth and extent of invasion into the lamina propria (T1 substaging) has been demonstrated to be of prognostic value in retrospective cohort studies [30, 31] (LE: 3). Its use is recommended by the most recent 2016 World Health Organization (WHO) classification [32]. The optimal system to substage T1 remains to be defined [32, 33].

### 4.4 Histological grading of non-muscle-invasive bladder urothelial carcinomas

In 2004, the WHO and the International Society of Urological Pathology published a new histological classification of urothelial carcinomas which provides a different patient stratification between individual categories compared to the older 1973 WHO classification [34, 35] (Tables 4.2 and 4.3, Figure 4.1). Recently an update of the 2004 WHO grading classification was published [32], but the following guidelines are still based on the 1973 and 2004 WHO classifications since most published data rely on these two classifications [8, 34, 35].




**Table 4.2: WHO grading in 1973 and in 2004 [34, 35]**

<p><b>1973 WHO grading</b>                  Grade 1: well differentiated                  Grade 2: moderately differentiated                  Grade 3: poorly differentiated</p> <p><b>2004 WHO grading system</b> (papillary lesions)                  Papillary urothelial neoplasm of low malignant potential (PUNLMP)                  Low-grade (LG) papillary urothelial carcinoma                  High-grade (HG) papillary urothelial carcinoma</p>
--

A recent systematic review and meta-analysis did not show that the 2004/2016 classification outperforms the 1973 classification in prediction of recurrence and progression [8] (LE: 2a).

There is a significant shift of patients between the prognostic categories of both systems, for example an increase in the number of HG patients (WHO 2004/2016) due to inclusion of some G2 patients with their better prognosis compared to G3 category (WHO 1973) [8]. As the 2004 WHO system has not been fully incorporated into prognostic models yet, long term individual patient data in both classification systems are needed.

**Figure 4.1: Stratification of tumours according to grade in the WHO 1973 and 2004 classifications [36]\***



**4.5 Carcinoma *in situ* and its classification**

Carcinoma *in situ* (CIS) is a flat, high-grade, non-invasive urothelial carcinoma. It can be missed or misinterpreted as an inflammatory lesion during cystoscopy if not biopsied. Carcinoma *in situ* is often multifocal and can occur in the bladder, but also in the upper urinary tract (UUT), prostatic ducts, and prostatic urethra [37].

Classification of CIS according to clinical type [38]:

- Primary: isolated CIS with no previous or concurrent papillary tumours and no previous CIS;
- Secondary: CIS detected during follow-up of patients with a previous tumour that was not CIS;
- Concurrent: CIS in the presence of any other urothelial tumour in the bladder.

**Table 4.3: WHO 2004 histological classification for flat lesions**

<ul style="list-style-type: none"> <li>• Urothelial proliferation of uncertain malignant potential (flat lesion without atypia or papillary aspects).</li> <li>• Reactive atypia (flat lesion with atypia).</li> <li>• Atypia of unknown significance.</li> <li>• Urothelial dysplasia.</li> <li>• Urothelial CIS is always high grade.</li> </ul>
--

## 4.6 Inter- and intra-observer variability in staging and grading

There is significant variability among pathologists for the diagnosis of CIS, for which agreement is achieved in only 70-78% of cases [39] (LE: 2a). There is also inter-observer variability in the classification of stage T1 vs. Ta tumours and tumour grading in both the 1973 and 2004 classifications. The general conformity in staging and grading is between 50% and 60% [40-43] (LE: 2a). The published comparisons have not clearly confirmed that the WHO 2004 classification provides better reproducibility than the 1973 classification [8, 40, 43-45].

## 4.7 Further pathology parameters

According to a meta-analysis of retrospective trials, the presence of lymphovascular invasion (LVI) in TURB specimens is connected with an increased risk of pathological upstaging [46] (LE: 3). Lymphovascular invasion has been reported as an unfavourable prognostic factor in T1 tumours [46-48] (LE: 3). Some variants of urothelial carcinoma (micropapillary, plasmocytoid, sarcomatoid) have a worse prognosis than classical urothelial carcinoma [2, 49-56] (LE: 3).

Molecular markers, particularly *FGFR3* mutation status, are promising but need further validation [57-61].

## 4.8 Summary of evidence and guidelines for bladder cancer classification

Summary of evidence	LE
The depth of invasion (staging) is classified according to the TNM classification.	2a
Papillary tumours confined to the mucosa and invading the lamina propria are classified as stage Ta and T1, respectively. Flat, high-grade tumours that are confined to the mucosa are classified as CIS (Tis).	2a
T1 and CIS, as compared to Ta, have high malignant potential; the term non-muscle-invasive bladder cancer (NMIBC) is therefore a suboptimal description.	3
For histological classification of NMIBC, both the WHO 1973 and 2004 grading systems are used.	2a

Recommendations	Strength rating
Use the 2017 TNM system for classification of the depth of tumour invasion (staging).	Strong
Use both the 1973 and 2004/2016 WHO grading systems for histological classification.	Strong
Do not use the term "superficial bladder cancer".	Strong
Mention the tumour stage and grade whenever the terminology NMIBC is used in individual cases.	Strong

# 5. DIAGNOSIS

## 5.1 Patient history

A comprehensive patient history is mandatory.

## 5.2 Signs and symptoms

Haematuria is the most common finding in NMIBC. Visible haematuria was found to be associated with higher stage disease compared to nonvisible haematuria at first presentation [62]. Carcinoma *in situ* might be suspected in patients with lower urinary tract symptoms, especially irritative voiding.

## 5.3 Physical examination

Physical examination does not reveal NMIBC. Ultrasound may be performed as an adjunct to physical examination as it has moderately high sensitivity to a wide range of abnormalities but cannot rule out all potential causes of haematuria [63].

## 5.4 Imaging

### 5.4.1 Computed tomography urography and intravenous urography

Computed tomography (CT) urography is used to detect papillary tumours in the urinary tract, indicated by filling defects or hydronephrosis.

Intravenous urography (IVU) is an alternative if CT is not available [64] (LE: 2b), but particularly in muscle-invasive tumours of the bladder and in UTUCs, CT urography gives more information than IVU (including status of lymph nodes and neighbouring organs).

The necessity to perform a baseline CT urography or IVU once a bladder tumour has been detected is questionable due to the low incidence of significant findings obtained [65-67] (LE: 2b). The incidence of UTUCs is low (1.8%), but increases to 7.5% in tumours located in the trigone [66] (LE: 2b). The risk of UTUC during follow up increases in patients with multiple- and high-risk tumours [68] (LE: 2b).

#### 5.4.2 **Ultrasound (US)**

Transabdominal US permits characterisation of renal masses, detection of hydronephrosis, and visualisation of intraluminal masses in the bladder [69] (LE: 3). Ultrasound is therefore a useful tool for detection of obstruction in patients with haematuria. However, it cannot exclude the presence of UTUC and cannot replace CT urography in bladder cancer detection.

The diagnosis of CIS cannot be made with imaging methods (CT urography, IVU or US) (LE: 4).

### 5.5 **Urinary cytology**

The examination of voided urine or bladder-washing specimens for exfoliated cancer cells has high sensitivity in G3 and high-grade tumours (84%), but low sensitivity in G1 and low-grade tumours (16%) [70]. The sensitivity in CIS detection is 28-100% [71] (LE: 1b). Cytology is useful, particularly as an adjunct to cystoscopy, if G3/CIS malignancy is present. Positive voided urinary cytology can indicate an urothelial tumour anywhere in the urinary tract; negative cytology, however, does not exclude the presence of a tumour.

Cytological interpretation is user-dependent [72]. Evaluation can be hampered by low cellular yield, urinary tract infections, stones, or intravesical instillations, however, in experienced hands specificity exceeds 90% [72] (LE: 2b).

A standardised reporting system redefining urinary cytology diagnostic categories was published in 2016 by the Paris Working Group [73]:

- Adequacy of urine specimens (Adequacy).
- Negative for high-grade urothelial carcinoma (Negative).
- Atypical urothelial cells (AUC).
- Suspicious for high-grade urothelial carcinoma (Suspicious).
- High-grade urothelial carcinoma (HGUC).
- Low-grade urothelial neoplasia (LGUN).

Urine collection should respect the recommendation provided in Section 5.9. One cytospin slide from the sample is usually sufficient [74]. In patients with suspicious cytology repeat investigation is advised [75] (LE: 2b).

### 5.6 **Urinary molecular marker tests**

Driven by the low sensitivity of urine cytology, numerous urinary tests were developed [76-79]. None of these markers have been accepted for diagnosis or follow-up in routine practice or clinical guidelines. A list of some of the more established urine tests (US Food and Drug Administration [FDA] approved and those for which multi-institutional data and multi-laboratory data are available) is listed in Table 5.1.

The following conclusions can be drawn regarding the existing tests:

- Sensitivity is usually higher at the cost of lower specificity, compared to urine cytology [76, 78-82] (LE: 3).
- Benign conditions and previous bacillus Calmette-Guérin (BCG) instillations influence many urinary marker tests [76, 78, 79] (LE: 1b).
- Requirements for sensitivity and specificity of a urinary marker test largely depend on the clinical context of the patient (screening, primary detection, follow up [high risk, low/intermediate risk]) [78, 79] (LE: 3).
- The wide range in performance of the markers listed in Table 5.1. and low reproducibility may be explained by patient selection and complicated laboratory methods required [79, 80, 83-90].
- Positive results of Cytology, UroVysion (FISH), NMP-22, Ucyt+, *FGFR3/TERT* and microsatellite analysis in patients with negative cystoscopy and upper tract work-up, may identify patients more likely to experience recurrence [84, 86, 89-92] and possibly progression [84, 86, 89-93] (LE: 2b).

**Table 5.1: Summary of more established urinary markers**

Markers (or test specifications)	Overall sensitivity (%)	Overall specificity (%)	Sensitivity for high-grade tumours (%)	Point-of-care test	LE
UroVysion (FISH)*	30-86	63-95	66-70	No	2b
Microsatellite analysis	58-92	73-100	90-92	No	1b
Immunocyt/uCyt +*	52-100	63-79	62-92	No	2a
Nuclear matrix Protein 22*	47-100	55-98	75-92	Yes	2a
BTA stat*	29-83	56-86	62-91	Yes	3
BTA TRAK*	53-91	28-83	74-77	No	3
Cytokeratins	12-88	73-95	33-100	No	3

BTA = bladder tumour antigen.

\* FDA approved.

## 5.7 Potential application of urinary cytology and markers

The following objectives of urinary cytology or molecular tests must be considered.

### 5.7.1 Screening of the population at risk of bladder cancer

The application of haematuria dipstick, *FGFR3*, *NMP22* or UroVysion in BC screening in high-risk populations has been reported [94, 95]. The low incidence of BC in the general population and the short lead-time impair feasibility and cost-effectiveness [92, 95]. Routine screening for BC is not recommended [92, 94, 95].

### 5.7.2 Exploration of patients after haematuria or other symptoms suggestive of bladder cancer (primary detection)

It is generally accepted that none of the currently available tests can replace cystoscopy. However, urinary cytology or biomarkers can be used as an adjunct to cystoscopy to detect invisible tumours, particularly CIS. In this setting, sensitivity for high-grade tumours and specificity are particularly important. Urinary cytology is highly specific, but urinary markers lack such high specificity and are not recommended for primary detection.

### 5.7.3 Surveillance of non-muscle-invasive bladder cancer

Research has been carried out into the usefulness of urinary cytology vs. markers in the follow up of NMIBC [83, 84, 96].

#### 5.7.3.1 Follow-up of high-risk non-muscle-invasive bladder cancer

High-risk tumours should be detected early in follow up, and the percentage of tumours missed should be as low as possible. Therefore, the best surveillance strategy for these patients will continue to include frequent cystoscopy and cytology.

#### 5.7.3.2 Follow-up of low/intermediate-risk non-muscle-invasive bladder cancer

To reduce the number of cystoscopy procedures, urinary markers should be able to detect recurrence before the tumours are large and numerous. The limitation of urinary cytology is its low sensitivity for low-grade recurrences. Several urinary markers are better, but still do not detect half of the low-grade tumours identified by cystoscopy [78, 84] (LE: 1b).


According to current knowledge, no urinary marker can replace cystoscopy during follow up or lower cystoscopy frequency in a routine fashion. One prospective randomised study found that knowledge of positive test results (microsatellite analysis) can improve the quality of follow-up cystoscopy [97] (LE: 1b), supporting the adjunctive role of a non-invasive urine test performed before follow-up cystoscopy [97].

## 5.8 Cystoscopy

The diagnosis of papillary BC ultimately depends on cystoscopic examination of the bladder and histological evaluation of sampled tissue by either cold-cup biopsy or resection. Carcinoma *in situ* is diagnosed by a combination of cystoscopy, urine cytology, and histological evaluation of multiple bladder biopsies [98].

Cystoscopy is initially performed as an outpatient procedure. A flexible instrument with topical intra-urethral anaesthetic lubricant instillation results in better compliance compared to a rigid instrument, especially in men [99, 100] (LE: 1b).

**Figure 5.1: Bladder diagram**



- 1 = Trigone
- 2 = Right ureteral orifice
- 3 = Left ureteral orifice
- 4 = Right wall
- 5 = Left wall
- 6 = Anterior wall
- 7 = Posterior wall
- 8 = Dome
- 9 = Neck
- 10 = Posterior urethra

**5.9 Summary of evidence and guidelines for the primary assessment of non-muscle-invasive bladder cancer**

Summary of evidence	LE
The diagnosis of bladder cancer depends on cystoscopy examination.	1
Urinary cytology has high sensitivity in high-grade tumours including carcinoma <i>in situ</i> .	2b

Recommendations	Strength rating
Take a patient history, focusing on urinary tract symptoms and haematuria.	Strong
Renal and bladder ultrasound and/or computed tomography-intravenous urography (CT-IVU) may be used during the initial work-up in patients with haematuria.	Weak
Once a bladder tumour has been detected, perform a computed tomography urography in selected cases (e.g., tumours located in the trigone, multiple- or high-risk tumours).	Strong
Perform cystoscopy in patients with symptoms suggestive of bladder cancer or during surveillance. It cannot be replaced by cytology or by any other non-invasive test.	Strong
In men, use a flexible cystoscope, if available.	Strong
Describe all macroscopic features of the tumour (site, size, number and appearance) and mucosal abnormalities during cystoscopy. Use a bladder diagram (Figure 5.1).	Strong
Use voided urine cytology as an adjunct to cystoscopy to detect high-grade tumour.	Strong
Perform cytology on fresh urine or urine with adequate fixation. Morning urine is not suitable because of the frequent presence of cytolysis.	Strong
Use the Paris system for cytology reporting.	Strong
Repeat urine cytology in patients with initial cytology results suspicious for high-grade urothelial carcinoma.	Weak

**5.10 Transurethral resection of TaT1 bladder tumours**

**5.10.1 Strategy of the procedure**

The goal of TURB in TaT1 BC is to make the correct diagnosis and completely remove all visible lesions. It is a crucial procedure in the diagnosis and treatment of BC. TURB should be performed systematically in individual steps [101] (see Section 5.14).

**5.10.2 Surgical and technical aspects of tumour resection**

**5.10.2.1 Surgical strategy of resection (resection in fractions, *en-bloc* resection)**

A complete resection is essential to achieve a good prognosis [102]. A complete resection can be achieved by either fractioned or *en-bloc* resection [101].

- Resection in fractions (separate resection of the exophytic part of the tumour, the underlying bladder wall and the edges of the resection area) provides good information about the vertical and horizontal extent of the tumour [103] (LE: 2b).
- *En-bloc* resection using monopolar or bipolar current, Thulium-YAG or Holmium-YAG laser is feasible in selected exophytic tumours. It provides high quality resected specimens with the presence of detrusor muscle in 96-100% of cases [101, 104-107] (LE: 1b).

The technique selected is dependent on the size and location of the tumour and experience of the surgeon.

#### 5.10.2.2 Evaluation of resection quality

It has been confirmed that the absence of detrusor muscle in the specimen is associated with a significantly higher risk of residual disease, early recurrence and tumour understaging [108] (LE: 1b). The presence of detrusor muscle in the specimen is considered as the surrogate criterion of the resection quality and is required (except of TaG1/LG tumours). It has been shown that surgical experience can improve TURB results, which supports the role of teaching programmes [109].

#### 5.10.2.3 Monopolar and bipolar resection

Compared to monopolar resection, bipolar resection has been introduced to reduce the risk of complications (e.g., bladder perforation due to obturator nerve stimulation) and to produce better specimens for the pathologist. Currently, the results remain controversial [110-113].

#### 5.10.2.4 Office-based fulguration and laser vaporisation

In patients with a history of small, TaLG/G1 tumours, fulguration of small papillary recurrences on an outpatient basis can reduce the therapeutic burden and is a treatment option [114] (LE: 3). There are no prospective comparative studies assessing the oncological outcomes.

Potassium titanyl-phosphate (KTP) laser vaporisation is associated with a low risk of complications. Its oncologic outcomes need to be confirmed in a larger patient population [115].

#### 5.10.2.5 Resection of small papillary bladder tumours at the time of transurethral resection of the prostate (TURP)

Only limited, retrospective, data exist on the outcome of incidentally detected papillary bladder tumour during cystoscopy as the initial step of TURP. Provided these tumours are papillary by aspect, rather small and not extensively multifocal, it seems feasible to resect these tumours and continue with the resection of the prostate. However, no exact risk-assessment can be provided [116, 117].

### 5.10.3 Bladder and prostatic urethral biopsies

Carcinoma *in situ* can present as a velvet-like, reddish, area indistinguishable from inflammation, or it may not be visible at all. For this reason, the strategy of taking biopsies from abnormal urothelium and biopsies from normal-looking mucosa (random/mapping biopsies) is recommended (see Section 5.14). The indication for random biopsies reflects the very low likelihood of detecting CIS, especially in low-risk tumours (< 2%) [118] (LE: 1b). The risk increases in patients with high-risk tumours and with positive cytology [119].

If equipment is available, photodynamic diagnosis (PDD) is a useful tool to target the biopsy (see Section 5.11.1). Involvement of the prostatic urethra and ducts in men with NMIBC has been reported. Palou *et al.* [120] showed that in 128 men with T1G3 BC, the incidence of CIS in the prostatic urethra was 11.7% (LE: 2b). The risk of prostatic urethra or duct involvement is higher if the tumour is located at the trigone or bladder neck, in the presence of bladder CIS and multiple tumours [121] (LE: 3b). Based on this observation, a biopsy from the prostatic urethra is necessary in some cases (see recommendation in Section 5.14) [120, 122].

## 5.11 New methods of tumour visualisation

As a standard procedure, cystoscopy and TURB are performed using white light. However, the use of white light can lead to missing lesions that are present but not visible, which is why new technologies are being developed.

### 5.11.1 Photodynamic diagnosis (fluorescence cystoscopy)

Photodynamic diagnosis (PDD) is performed using violet light after intravesical instillation of 5-aminolaevulinic acid (ALA) or hexaminolaevulinic acid (HAL). It has been confirmed that fluorescence-guided biopsy and resection are more sensitive than conventional procedures for the detection of malignant tumours, particularly for CIS [123, 124] (LE: 1a). In a systematic review and meta-analysis, PDD had higher sensitivity than white light endoscopy in the pooled estimates for analyses at both the patient-level (92% vs.71%) and biopsy-level (93% vs. 65%) [124]. A prospective randomised trial did not confirm a higher detection rate in patients with known positive cytology before TURB [125].

Photodynamic diagnosis had lower specificity than white-light endoscopy (63% vs. 81%) [124]. False-positivity can be induced by inflammation or recent TURB and during the first three months after BCG instillation [126, 127] (LE: 1a).

The beneficial effect of ALA or HAL FC on recurrence rate in patients with TURB was evaluated by more prospective, randomised trials. The meta-analysis of 14 RCTs evaluating ALA or HAL FC published in 2017 demonstrated reduced recurrence rates in patients with FC guided TURB [128] (LE: 1a).

The value of fluorescence-guided TURB for the improvement of outcome in relation to progression rate, survival and clinical management remains to be demonstrated.

#### 5.11.2 **Narrow-band imaging**

In narrow-band imaging (NBI), the contrast between normal urothelium and hyper-vascular cancer tissue is enhanced. Cohort studies have demonstrated improved cancer detection by NBI flexible cystoscopy and NBI-guided biopsies and resection [129-131] (LE: 3b). The reduction of recurrence rate if NBI is used during TURB has been confirmed after three and twelve months for low-risk tumours (pTaLG, < 30 mm, no CIS) [132] (LE: 1b).

### 5.12 **Second resection**

The significant risk of residual tumour after initial TURB of TaT1 lesions has been demonstrated [102] (LE: 1b). Persistent disease after resection of T1 tumours has been observed in 33-55% of patients, after resection of TaG3 tumour in 41.4% [133-136]. Moreover, the tumour is often understaged in the initial resection. The likelihood that muscle-invasive disease is detected by second resection of initially T1 tumour ranges from 1.3-25%, and increases to 45% if there was no muscle in the initial resection [125, 137-140]. This risk increased to 50% in some radical cystectomy (RC) series, although these studies only enrolled selected patients [141-143] (LE: 2a). Treatment of a TaT1 high-grade tumour and a T2 tumour is completely different; correct staging is therefore important. It has been demonstrated that a second TURB can increase recurrence-free survival [133, 134] (LE: 2a), improve outcomes after BCG treatment [144] (LE: 3) and provide prognostic information [139, 141, 145] (LE: 3).

In a retrospective evaluation of a large multi-institutional cohort of 2,451 patients with BCG-treated T1G3/HG tumours (second resection was performed in 935 patients), the second resection improved recurrence-free survival (RFS), progression-free survival (PFS) and overall survival (OS) only in patients without muscle in the specimen from initial resection [146] (LE: 3).

According to a meta-analysis of published trials, the prevalence rate for residual tumours and upstaging to invasive disease remains high even in the subgroup of T1 tumours with muscle in the specimen. In the total population of 3,556 patients with T1 tumours, disease persistence was detected in 61% and tumour understaging in 15% of cases, whereas in the subgroup of 1,565 T1 tumours with muscle presence, the risk was 58% and 11%. The analysis, however, showed significant heterogeneity between studies [147].

Retrospective evaluation showed that a second resection performed 14-42 days after initial resection provides longer RFS and PFS compared to second resection performed after 43-90 days [148] (LE: 3). Based on these arguments, a second TURB is recommended in selected cases two-six weeks after initial resection (for recommendations on patient selection, see Section 5.14).

The results of the second resection (residual tumours and understaging) reflect the quality of the initial TURB. As the goal is to improve the quality of the initial TURB, the results of the second resection should be recorded.

### 5.13 **Pathology report**

Pathological investigation of the specimen(s) obtained by TURB and biopsies is an essential step in the diagnosis and treatment decision-making process for BC [149]. Close co-operation between urologists and pathologists is required. A high quality of resected and submitted tissue and clinical information is essential for correct pathological assessment. The presence of sufficient muscle is necessary for the correct assignment of the T category. To obtain all relevant information, the specimen collection, handling and evaluation should respect the recommendations provided below (see Section 5.14) [150]. In difficult cases, an additional review by an experienced genitourinary pathologist should be considered.

## 5.14 Summary of evidence and guidelines for transurethral resection of the bladder, biopsies and pathology report

Summary of evidence	LE
Transurethral resection of the bladder (TURB) followed by pathology investigation of the obtained specimen(s) is an essential step in the treatment of NMIBC.	1
The absence of detrusor muscle in the specimen is associated with a significantly higher risk of residual disease and tumour understaging.	2b
In patients with a history of small, TaLG/G1 tumours, fulguration of small papillary recurrences on an outpatient basis is feasible and safe.	3
A second TURB can detect residual tumours and tumour understaging, increase recurrence-free survival, improve outcomes after BCG treatment and provide prognostic information.	2

Recommendations	Strength rating
In patients suspected of having bladder cancer, perform a TURB followed by pathology investigation of the obtained specimen(s) as a diagnostic procedure and initial treatment step.	Strong
Perform TURB systematically in individual steps: <ul style="list-style-type: none"> <li>• bimanual palpation under anaesthesia;</li> <li>• insertion of the resectoscope, under visual control with inspection of the whole urethra;</li> <li>• inspection of the whole urothelial lining of the bladder;</li> <li>• biopsy from the prostatic urethra (if indicated);</li> <li>• cold-cup bladder biopsies (if indicated);</li> <li>• resection of the tumour;</li> <li>• recording of findings in the surgery report/record;</li> <li>• precise description of the specimen for pathology evaluation.</li> </ul>	Strong
<b>Performance of individual steps</b>	
Perform <i>en-bloc</i> resection or resection in fractions (exophytic part of the tumour, the underlying bladder wall and the edges of the resection area). The presence of detrusor muscle in the specimen is required in all cases except for TaG1/LG tumours.	Strong
Avoid cauterisation as much as possible during TURB to avoid tissue deterioration.	Strong
Take biopsies from abnormal-looking urothelium. Biopsies from normal-looking mucosa (trigone, bladder dome, and right, left, anterior and posterior bladder wall) are recommended when cytology is positive or when high-risk exophytic tumour is expected (non-papillary appearance). If equipment is available, perform fluorescence-guided (PDD) biopsies.	Strong
Take biopsy of the prostatic urethra in cases of bladder neck tumour, when bladder carcinoma <i>in situ</i> is present or suspected, when there is positive cytology without evidence of tumour in the bladder, or when abnormalities of the prostatic urethra are visible. If biopsy is not performed during the initial procedure, it should be completed at the time of the second resection.	Strong
Take the biopsy from abnormal areas in the prostatic urethra and from the precollicular area (between the 5 and 7 o'clock position) using a resection loop. In primary non-muscle-invasive tumours when stromal invasion is not suspected, cold-cup biopsy with forceps can be used.	Weak
Use methods to improve tumour visualization (FC, NBI) during TURB, if available.	Weak
Refer the specimens from different biopsies and resection fractions to the pathologist in separately labelled containers.	Weak
The TURB protocol must describe tumour appearance, all steps of the procedure, as well as the extent and completeness of resection.	Strong
In patients with positive cytology, but negative cystoscopy, exclude an upper tract urothelial carcinoma, CIS in the bladder (random biopsies or PDD-guided biopsies) and tumour in the prostatic urethra (prostatic urethra biopsy).	Strong
Perform a second TURB in the following situations: <ul style="list-style-type: none"> <li>• after incomplete initial TURB, or in case of doubt about completeness of a TURB);</li> <li>• if there is no muscle in the specimen after initial resection, with the exception of TaLG/G1 tumours and primary CIS;</li> <li>• in T1 tumours.</li> </ul>	Strong



If indicated, perform a second TURB within two-six weeks after initial resection. This second TURB should include resection of the primary tumour site.	Weak
Register the pathology results of a second TURB as it reflects the quality of the initial resection.	Weak
Inform the pathologist of prior treatments (intravesical therapy, radiotherapy, etc.).	Strong
<b>Pathological report</b>	
The pathological report should specify tumour location, tumour grade, depth of tumour invasion, presence of CIS, and whether the detrusor muscle is present in the specimen.	Strong
The pathological report should specify the presence of lymphovascular invasion or unusual (variant) histology.	Strong

## 6. PREDICTING DISEASE RECURRENCE AND PROGRESSION

### 6.1 TaT1 tumours

Treatment should be based on a patient's prognosis. In order to predict, separately, the short- and long-term risks of disease recurrence and progression in individual patients, the EORTC Genito-Urinary Cancer Group has developed a scoring system and risk tables [151]. The basis for these tables are individual patient data from 2,596 patients diagnosed with TaT1 tumours, who were randomised into seven EORTC trials. Patients with CIS alone were not included. Seventy-eight percent of patients received intravesical treatment, mostly chemotherapy. However, they did not undergo a second TURB or receive maintenance BCG.

The scoring system is based on the six most significant clinical and pathological factors which are shown in Table 6.1. It also illustrates the weights applied to various factors for calculating the total scores for recurrence and progression. Table 6.2 shows the total scores stratified, into four categories that reflect various probabilities of recurrence and progression at one and five years [151] (LE: 2a).

**Table 6.1: Weighting used to calculate disease recurrence and progression scores**

Factor	Recurrence	Progression
Number of tumours		
Single	0	0
2-7	3	3
≥ 8	6	3
Tumour diameter		
< 3 cm	0	0
≥ 3	3	3
Prior recurrence rate		
Primary	0	0
≤ 1 recurrence/year	2	2
> 1 recurrence/year	4	2
Category		
Ta	0	0
T1	1	4
Concurrent CIS		
No	0	0
Yes	1	6
Grade		
G1	0	0
G2	1	0
G3	2	5
<b>Total Score</b>	<b>0-17</b>	<b>0-23</b>

**Table 6.2: Probability of recurrence and disease progression according to total score**

Recurrence score	Probability of recurrence at 1 year		Probability of recurrence at 5 years	
	%	(95% CI)	%	(95% CI)
0	15	(10-19)	31	(24-37)
1-4	24	(21-26)	46	(42-49)
5-9	38	(35-41)	62	(58-65)
10-17	61	(55-67)	78	(73-84)

Progression score	Probability of progression at 1 year		Probability of progression at 5 years	
	%	(95% CI)	%	(95% CI)
0	0.2	(0-0.7)	0.8	(0-1.7)
2-6	1	(0.4-1.6)	6	(5-8)
7-13	5	(4-7)	17	(14-20)
14-23	17	(10-24)	45	(35-55)

NB: Electronic calculators for Tables 6.1 and 6.2, which have been updated for Apple and Android phones and tablets, and are available at <http://www.eortc.be/tools/bladdercalculator/>.

The prognosis of intermediate-risk patients treated with chemotherapy has been calculated in a recently published paper. Patients with Ta G1/G2 tumours receiving chemotherapy were further stratified into three risk groups for recurrence, taking into account the history of recurrences, history of intravesical treatment, tumour grade, number of tumours and adjuvant chemotherapy [152].

A scoring model for BCG-treated patients that predicts the short- and long-term risks of recurrence and progression has been published by the Club Urológico Español de Tratamiento Oncológico (CUETO) (Spanish Urological Oncology Group). It is based on an analysis of 1,062 patients from four CUETO trials that compared different intravesical BCG treatments. Patients received twelve instillations over five-six months. No immediate post-operative instillation or second TURB was performed in these patients. The scoring system is based on the evaluation of seven prognostic factors:

- gender;
- age;
- prior recurrence status;
- number of tumours;
- T category;
- associated CIS;
- tumour grade.

Using these tables, the calculated risk of recurrence is lower than that obtained by the EORTC tables. For progression, probability is lower only in high-risk patients [153] (LE: 2a). The lower risks in the CUETO tables may be attributed to the use of BCG in this sample, which is a more effective instillation therapy. The CUETO risk calculator is available at: <http://www.aeu.es/Cueto.html>.

The prognostic value of the EORTC scoring system has been confirmed by data from the CUETO patients treated with BCG and by long-term follow up in an independent patient population [154, 155] (LE: 2a).

In 1,812 intermediate- and high-risk patients without CIS treated with one to three years of maintenance BCG, the EORTC found that the prior disease-recurrence rate and number of tumours were the most important prognostic factors for disease recurrence, stage and grade were the most important prognostic factors for disease progression and disease-specific survival, while age and grade were the most important prognostic factors for OS. T1G3 patients do poorly, with one- and five-year disease-progression rates of 11.4% and 19.8%, respectively. Using these data the new EORTC risk groups and nomograms for BCG treated patients were designed [156] (LE: 2a).

Further prognostic factors have been described in selected patient populations:

- In T1G3 tumours important prognostic factors were female sex, CIS in the prostatic urethra in men treated with an induction course of BCG, and age, tumour size and concurrent CIS in BCG-treated patients (62% with induction course only) [120, 157] (LE: 2b).
- Attention must be given to patients with T1G3 tumours in bladder (pseudo) diverticulum because of the absence of muscle layer in the diverticular wall [158] (LE: 3).

- In patients with high-risk disease, the tumour stage at the time of the second TURB is an unfavourable prognostic factor [141, 145] (LE: 3).
- In patients with T1G2 tumours treated with TURB, recurrence at three months was the most important predictor of progression [159] (LE: 2b).
- The prognostic value of pathological factors has been discussed elsewhere (see Section 4.6). More research is needed to determine the role of molecular markers in improving the predictive accuracy of currently available risk tables [154, 160].

## 6.2 Carcinoma *in situ*

Without any treatment, approximately 54% of patients with CIS progress to muscle-invasive disease [161] (LE: 3). Unfortunately, there are no reliable prognostic factors that can be used to predict the course of the disease. Publications are based on retrospective analyses of small series of patients and conclusions are not homogeneous. Some studies have reported a worse prognosis in concurrent CIS and T1 tumours compared to primary CIS [162, 163], extended CIS [164] and CIS in the prostatic urethra [120] (LE: 3).

The response to intravesical treatment with BCG or chemotherapy is an important prognostic factor for subsequent progression and death caused by BC [153-155, 159]. Approximately 10-20% of complete responders eventually progress to muscle-invasive disease, compared with 66% of non-responders [165, 166] (LE: 2a).

## 6.3 Patient stratification into risk groups

To facilitate treatment recommendations it is important to categorise patients into risk groups. Based on available prognostic factors and, in particular, data from the EORTC risk tables, the Guidelines Panel recommends stratification of patients into three risk groups. Table 6.3 provides a definition of these risk groups, which takes into account the EORTC risk tables' probabilities of recurrence and, especially, progression.

## 6.4 Subgroup of highest-risk tumours

Based on prognostic factors, it is possible to substratify high-risk group patients, and identify those that are at the highest risk of disease progression. Patients diagnosed with T1G3/HG tumours associated with concurrent bladder CIS, multiple- and/or large T1G3/HG tumours and/or recurrent T1G3/HG, T1G3/HG with CIS in the prostatic urethra, some forms of variant histology of urothelial carcinoma, and T1 tumours with LVI (Table 6.3) are at the highest risk of progression.

**Table 6.3: Risk group stratification**

Risk group stratification	Characteristics
Low-risk tumours	Primary, solitary, TaG1 (PUNLMP, LG*), < 3 cm, no CIS
Intermediate-risk tumours	All tumours not defined in the two adjacent categories (between the category of low- and high risk).
High-risk tumours	Any of the following: <ul style="list-style-type: none"> <li>• T1 tumour</li> <li>• G3 (HG**) tumour</li> <li>• carcinoma <i>in situ</i> (CIS)</li> <li>• Multiple, recurrent and large (&gt; 3 cm) TaG1G2 /LG tumours (all features must be present)*.</li> </ul>
	<b>Subgroup of highest risk tumours:</b>
	T1G3/HG associated with concurrent bladder CIS, multiple- and/or large T1G3/HG and/or recurrent T1G3/HG, T1G3/HG with CIS in the prostatic urethra, some forms of variant histology of urothelial carcinoma, lymphovascular invasion.

*Substratification of high-risk tumours for clinical purposes is addressed in Table 7.2.*

\*Low grade is a mixture of G1 and G2.

\*\* High grade is a mixture of some G2 and all G3 (see Figure 4.1).

## 6.5 Summary of evidence and guidelines for stratification of non-muscle-invasive bladder cancer

Summary of evidence	LE
The EORTC scoring system and risk tables predict the short- and long-term risks of disease recurrence and progression in individual patients with non-muscle-invasive bladder cancer (NMIBC).	2a
Patients with Ta G1/G2 tumours receiving chemotherapy have been further stratified into three risk groups for recurrence, taking into account the history of recurrences, history of intravesical treatment, tumour grade, number of tumours and adjuvant chemotherapy.	2a-b
In patients treated with BCG, the CUETO scoring model predicts the short- and long-term risks of disease recurrence and progression.	2a
In patients receiving BCG maintenance; prior recurrence rate and number of tumours are the most important prognostic factors for disease recurrence.	2a
Stage and grade are the most important prognostic factors for disease progression and disease specific survival.	2a
Patient age and grade are the most important prognostic factors for overall survival.	2a

Recommendations	Strength rating
Stratify patients into three risk groups according to Table 6.3.	Strong
Apply the EORTC risk tables and calculator for the prediction of the risk of tumour recurrence and progression in different intervals after transurethral resection of the bladder, in individual patients.	Strong
Use the CUETO risk tables and the new EORTC risk groups for the prediction of the risk of tumour recurrence and progression in individual patients treated with bacillus Calmette-Guérin.	Strong

## 7. DISEASE MANAGEMENT

### 7.1 Counselling of smoking cessation

It has been confirmed that smoking increases the risk of tumour recurrence and progression [167, 168] (LE: 3). While it is still controversial whether smoking cessation in BC will favourably influence the outcome of BC treatment, patients should be counselled to stop smoking due to the general risks connected with tobacco smoking [169-172] (LE: 3).

### 7.2 Adjuvant treatment

#### 7.2.1 Intravesical chemotherapy

Although TURB by itself can eradicate a TaT1 tumour completely, these tumours commonly recur and can progress to MIBC. The high variability in the three-month recurrence rate indicates that the TURB was incomplete or provokes recurrences in a high percentage of patients [102]. It is therefore necessary to consider adjuvant therapy in all patients.

##### 7.2.1.1 A single, immediate, post-operative intravesical instillation of chemotherapy

Immediate single instillation (SI) has been shown to act by destroying circulating tumour cells after TURB, and by an ablative effect (chemo resection) on residual tumour cells at the resection site and on small overlooked tumours [173-176] (LE: 3).

Four large meta-analyses comprising 1,476 to 3,103 patients have consistently shown that after TURB, SI significantly reduces the recurrence rate compared to TURB alone [177-180] (LE: 1a). In the most recent systematic review and individual patient data meta-analysis of 2,278 eligible patients [177], SI reduced the five-year recurrence rate by 14%, from 59% to 45%. The number to treat (NNT) to prevent one recurrence within five years was seven eligible patients. Only patients with a prior recurrence rate of less than or equal to one recurrence per year and those with an EORTC recurrence score < 5 benefited from SI. In patients with an EORTC recurrence score ≥ 5 and/or patients with a prior recurrence rate of > 1 recurrence per year, SI was not effective as a single adjuvant treatment. Mitomycin C (MMC), epirubicin, and pirarubicin have all shown a beneficial effect [177]. No randomised comparisons of individual drugs have been conducted [177-180] (LE: 1a).

Prevention of tumour cell implantation should be initiated within the first few hours after TURB. After that, tumour cells are firmly implanted and are covered by the extracellular matrix [173, 181, 182] (LE: 3). In all SI studies, the instillation was administered within 24 hours. To maximise the efficacy of SI, one should devise flexible practices that allow the instillation to be given as soon as possible after TURB, preferably within the first two hours in the recovery room or even in the operating theatre. As severe complications have been reported in patients with drug extravasation [183, 184] safety measures should be maintained (see Section 7.5).

#### 7.2.1.2 *Additional adjuvant intravesical chemotherapy instillations*

The need for further adjuvant intravesical therapy depends on prognosis. In low-risk patients (Tables 6.1, 6.2 and 6.3), a SI reduces the risk of recurrence and is considered to be the standard and complete treatment [177, 178] (LE: 1a). For other patients, however, a SI remains an incomplete treatment because of the considerable likelihood of recurrence and/or progression (Tables 6.1, 6.2 and 6.3).

Efficacy data for the following comparisons were published:

##### *Single installation only vs. SI + further repeat instillations*

In one study [185], further chemotherapy instillations after SI improved recurrence-free survival in intermediate-risk patients (LE: 2a).

##### *Repeat chemotherapy instillations vs. no adjuvant treatment*

A large meta-analysis of 3,703 patients from eleven randomised trials showed a highly significant (44%) reduction in the odds of recurrence at one year in favour of chemotherapy over TURB alone [186]. This corresponds to an absolute difference of 13-14% in the number of patients with recurrence. Contrary to these findings, two meta-analyses have demonstrated that BCG therapy may reduce the risk of tumour progression [187, 188] (LE: 1a) (see Section 7.2.2.1). Moreover, BCG maintenance therapy appears to be significantly better in preventing recurrences than chemotherapy [189-191] (see Section 7.2.2.1) (LE: 1a). However, BCG causes significantly more side effects than chemotherapy [191] (LE: 1a).

##### *Single instillation + further repeat instillations vs. later repeat instillations only*

There is evidence from several studies in intermediate-risk patients that SI might have an impact on recurrence even when further adjuvant instillations are given [192-195]. A recent RCT including 2,243 NMIBC patients, which compared SI of MMC with an instillation of MMC delayed two weeks after TURBT (followed by further repeat instillations in both treatment arms), showed a significant reduction of 9% in the risk of recurrence at three years in favour of SI, from 36% to 27%. The effect was significant in the intermediate- and high-risk groups of patients receiving additional adjuvant MMC instillations [192] (LE: 2a). Unfortunately, the authors' definition of risk groups differed significantly from those currently recommended. As a consequence, some patients did not receive adequate therapy and the study cannot reliably answer the question of whether SI improves the efficacy of further instillations [192].

The length and frequency of repeat chemotherapy instillations is still controversial. A SR of RCTs, comparing different schedules of intravesical chemotherapy instillations, concluded that the ideal duration and intensity of the schedule remains undefined because of conflicting data [195]. The available evidence does not support treatment longer than one year (LE: 3).

#### 7.2.1.3 *Options for improving efficacy of intravesical chemotherapy*

##### 7.2.1.3.1 *Adjustment of pH, duration of instillation, and drug concentration*

One RCT using MMC has demonstrated that adapting urinary pH, decreasing urinary excretion, and buffering the intravesical solution reduced the recurrence rate [196] (LE: 1b). Another trial reported that duration of a one hour instillation of MCC was more effective compared to a 30 minute instillation, but no efficacy comparisons are available for one- vs. two-hour durations of instillation [197] (LE: 3). Another RCT using epirubicin has documented that concentration is more important than treatment duration [198] (LE: 1b). In view of these data, instructions are provided (see Section 7.5).

##### 7.2.1.3.2 *Device-assisted intravesical chemotherapy*

###### *Microwave-induced hyperthermia*

Promising data have been presented on enhancing the efficacy of MMC using microwave-induced hyperthermia in patients with high-risk tumours [199]. In one RCT comparing one year of BCG with one year MMC and microwave-induced hyperthermia in patients with intermediate- and high-risk bladder cancer, a reduced RFS at 24 months in the MMC group was demonstrated [200] (LE: 1b).

### *Hyperthermic intravesical chemotherapy*

Different technologies which increase the temperature of instilled MMC are available, however, data about their efficacy are still lacking.

### *Electromotive drug administration (EMDA)*

The efficacy of MMC using EMDA sequentially combined with BCG in patients with high-risk tumours has been demonstrated in one small RCT [201]. The definitive conclusion however, needs further confirmation.

#### 7.2.1.4 Summary of evidence - intravesical chemotherapy

Summary of evidence	LE
In patients with non-muscle-invasive bladder cancer and a prior low recurrence rate ( $\leq$ to one recurrence per year) and in those with an EORTC recurrence score $< 5$ , a single instillation (SI) significantly reduces the recurrence rate compared to transurethral resection of the bladder alone.	1a
Single instillation might have an impact on recurrence even when further adjuvant chemotherapy instillations are given.	3
Repeat chemotherapy instillations (with or without previous SI) improve recurrence-free survival in intermediate-risk patients.	2a

### 7.2.2 **Intravesical bacillus Calmette-Guérin (BCG) immunotherapy**

#### 7.2.2.1 Efficacy of BCG

Five meta-analyses have confirmed that BCG after TURB is superior to TURB alone or TURB + chemotherapy for preventing the recurrence of NMIBC [189, 202-205] (LE: 1a). Three recent RCTs of intermediate- and high-risk tumours have compared BCG with epirubicin + interferon [206], MMC [207], or epirubicin alone [190] and have confirmed the superiority of BCG for prevention of tumour recurrence (LE: 1a). The effect is longlasting [190, 207] and was also observed in a separate analysis of patients with intermediate-risk tumours [190].

One meta-analysis [189] has evaluated the individual data from 2,820 patients enrolled in nine RCTs that have compared MMC vs. BCG. In the trials with BCG maintenance, there was a 32% reduction in the risk of recurrence for BCG compared to MMC, but a 28% increase in the risk of recurrence for patients treated with BCG in the trials without BCG maintenance.

Two meta-analyses have demonstrated that BCG therapy delays and potentially lowers the risk of tumour progression [187, 188] (LE: 1a). A meta-analysis carried out by the EORTC-Genito Urinary Cancers Group (GUCCG) has evaluated data from 4,863 patients enrolled in 24 RCTs. Five different BCG strains were used, and in 20 of the trials, some form of BCG maintenance was used. Based on a median follow-up of 2.5 years, in 260 out of 2,658 patients (9.8%) treated with BCG, tumours progressed, compared to 304 out of 2,205 (13.8%) in the control groups (TURB alone, TURB + intravesical chemotherapy, or TURB + other immunotherapy). This shows a reduction of 27% in the odds of progression with BCG maintenance treatment. The size of the reduction was similar in patients with TaT1 papillary tumours and in those with CIS [188]. A recent RCT with long-term observation has demonstrated significantly fewer distant metastases and better overall- and disease-specific survival in patients treated with BCG compared to epirubicin [190] (LE: 1b). In contrast, a meta-analysis of individual patient data was not able to confirm any statistically significant difference between MMC and BCG for progression, survival and cause of death [189].

The conflicting results in the outcomes of these studies can be explained by different patient characteristics, duration of follow-up, methodology and statistical power. However, most studies showed a reduction in the risk of progression in high- and intermediate-risk tumours if BCG was applied including a maintenance schedule.

Two other meta-analyses have suggested a possible bias in favour of BCG arising from the inclusion of patients previously treated with intravesical chemotherapy [208]. In the most recent meta-analysis, however, BCG maintenance was more effective than MMC, both in patients previously treated and not previously treated with chemotherapy [189] (LE: 1a). It was demonstrated that BCG was less effective in patients  $> 70$  years of age, but still more effective than epirubicin in a cohort of elderly patients [209] (LE: 1a).

#### 7.2.2.2 BCG strain

The EORTC meta-analysis suggested no large differences in efficacy between various BCG strains [188]. Recently published smaller studies without maintenance demonstrated some differences between strains. This clearly needs further evaluation in prospective trials [210, 211] (LE: 2a).

### 7.2.2.3 BCG toxicity

Bacillus Calmette-Guérin intravesical treatment is associated with more side effects compared to intravesical chemotherapy [188] (LE: 1a). However, serious side effects are encountered in < 5% of patients and can be treated effectively in almost all cases [212] (LE: 1b). It has been shown that a maintenance schedule is not associated with an increased risk of side effects compared to an induction course [212]. Side effects requiring treatment stoppage were seen more often in the first year of therapy [213]. Elderly patients do not seem to experience more side effects leading to treatment discontinuation [214] (LE: 2a).

Major complications can appear after systemic absorption of the drug. Thus, contraindications of BCG intravesical instillation should be respected (see Section 7.5). The presence of leukocyturia, nonvisible haematuria or asymptomatic bacteriuria is not a contraindication for BCG application, and antibiotic prophylaxis is not necessary in these cases [215, 216] (LE: 3).

Bacillus Calmette-Guérin should be used with caution in immunocompromised patients; e.g. immunosuppression, human immunodeficiency virus [HIV] infection pose relative contraindications [217], although some small studies have shown similar efficacy and no increase in complications compared to non-immunocompromised patients. The role of prophylactic anti-tuberculosis medication in these patients remains unclear [218-220] (LE: 3). The management of side effects after BCG should reflect their type and grade according to the recommendations provided by the International Bladder Cancer Group (IBCG) and by a Spanish group [221, 222] (Table 7.1).

**Table 7.1: Management options for side effects associated with intravesical bacillus Calmette-Guérin (BCG) [222-225]**

<b>Management options for local side effects (modified from International Bladder Cancer Group)</b>	
<b>Symptoms of cystitis</b>	Phenazopyridine, propantheline bromide, or non-steroidal anti-inflammatory drugs (NSAIDs)
	If symptoms improve within a few days: continue instillations
	If symptoms persist or worsen: <ol style="list-style-type: none"> <li>Postpone the instillation</li> <li>Perform a urine culture</li> <li>Start empirical antibiotic treatment</li> </ol>
	If symptoms persist even with antibiotic treatment: <ol style="list-style-type: none"> <li>With positive culture: adjust antibiotic treatment according to sensitivity</li> <li>With negative culture: quinolones and potentially analgesic anti-inflammatory instillations once daily for 5 days (repeat cycle if necessary) [223].</li> </ol>
	If symptoms persist: anti-tuberculosis drugs + corticosteroids.
	If no response to treatment and/or contracted bladder: radical cystectomy.
<b>Haematuria</b>	Perform urine culture to exclude haemorrhagic cystitis, if other symptoms present.
	If haematuria persists, perform cystoscopy to evaluate presence of bladder tumour.
<b>Symptomatic granulomatous prostatitis</b>	Symptoms rarely present: perform urine culture.
	Quinolones.
	If quinolones are not effective: isoniazid (300 mg/day) and rifampicin (600 mg/day) for three months.
	Cessation of intravesical therapy.
<b>Epididymo-orchitis</b> [224]	Perform urine culture and administer quinolones.
	Cessation of intravesical therapy.
	Orchidectomy if abscess or no response to treatment.
<b>Management options for systemic side effects</b>	
<b>General malaise, fever</b>	Generally resolve within 48 hours, with or without antipyretics.
<b>Arthralgia and/or arthritis</b>	Rare complication and considered autoimmune reaction.
	Arthralgia: treatment with NSAIDs.
	Arthritis: NSAIDs.
	If no/partial response, proceed to corticosteroids, high-dose quinolones or antituberculosis drugs [225].
<b>Persistent high-grade fever (&gt; 38.5°C for &gt; 48 h)</b>	Permanent discontinuation of BCG instillations.
	Immediate evaluation: urine culture, blood tests, chest X-ray.
	Prompt treatment with more than two antimicrobial agents while diagnostic evaluation is conducted.
	Consultation with an infectious diseases specialist.

<b>BCG sepsis</b>	Prevention: initiate BCG at least 2 weeks post-transurethral resection of the bladder (if no signs and symptoms of haematuria).
	Cessation of BCG.
	For severe infection: <ul style="list-style-type: none"> <li>• High-dose quinolones or isoniazid, rifampicin and ethambutol 1.2 g daily for 6 months.</li> <li>• Early, high-dose corticosteroids as long as symptoms persist.</li> <li>• Consider an empirical non-specific antibiotic to cover Gram-negative bacteria and/or <i>Enterococcus</i>.</li> </ul>
<b>Allergic reactions</b>	Antihistamines and anti-inflammatory agents.
	Consider high-dose quinolones or isoniazid and rifampicin for persistent symptoms.
	Delay therapy until reactions resolve.

#### 7.2.2.4 Optimal BCG schedule

Induction BCG instillations are given according to the empirical six-weekly schedule introduced by Morales [226]. For optimal efficacy, BCG must be given in a maintenance schedule [187-189, 205] (LE: 1a). Many different maintenance schedules have been used, ranging from a total of ten instillations given in eighteen weeks to 27 over three years [227]. The EORTC meta-analysis was unable to determine which BCG maintenance schedule was the most effective [188]. In their meta-analysis, Böhle *et al.* concluded that at least one year of maintenance BCG is required to obtain superiority of BCG over MMC for prevention of recurrence or progression [187] (LE: 1a).

The optimal number of induction instillations and the optimal frequency and duration of maintenance instillations is not fully known. Moreover, it can be different in each individual patient [228]. In a RCT of 1,355 patients, the EORTC has shown that when BCG is given at full dose, three years' maintenance (three-weekly instillations 3, 6, 12, 18, 24, 30 and 36 months) reduces the recurrence rate compared to one year in high- but not in intermediate-risk patients. There were no differences in progression or OS. In the three-year arm, however, 36.1% of patients did not complete the three-year schedule [229] (LE: 1b). In a RCT of 397 patients CUETO suggested that in high-risk tumours, the maintenance schedule with only one instillation every three months for three years may be suboptimal [230] (LE: 1b).

#### 7.2.2.5 Optimal dose of BCG

To reduce BCG toxicity, instillation of a reduced dose was proposed. However, it has been suggested that a full dose of BCG is more effective in multifocal tumours [231, 232] (LE: 1b). The CUETO study compared one-third dose to full-dose BCG and found no overall difference in efficacy. One-third of the standard dose of BCG might be the minimum effective dose for intermediate-risk tumours. A further reduction to one-sixth dose resulted in a decrease in efficacy with no decrease in toxicity [233] (LE: 1b).

The EORTC did not find any difference in toxicity between one-third and full-dose BCG, but one third dose BCG was associated with a higher recurrence rate, especially when it was given only for one year [213, 229] (LE: 1b). The routine use of one-third dose BCG is complicated by potential technical difficulties in preparing the reduced dose reliably, given uneven distribution of colony-forming-units in the dry product formulation.

#### 7.2.2.6 Indications for BCG

Although BCG is very effective, there is consensus that not all patients with NMIBC should be treated with BCG due to the risk of toxicity. Ultimately, the choice of treatment depends upon the patient's risk (Table 6.2). The recommendation for individual risk groups is provided in Section 7.5.

A statement by the Panel on BCG shortage can be accessed online: <https://uroweb.org/guideline/non-muscleinvasive-bladder-cancer/?type=appendices-publications>.

#### 7.2.2.7 Summary of evidence - BCG treatment

Summary of evidence	LE
In patients with intermediate- and high-risk tumours, intravesical bacillus Calmette-Guérin (BCG) after TURB reduces the risk of tumour recurrence; it is more effective than TURB alone or TURB + intravesical chemotherapy.	1a
For optimal efficacy, BCG must be given in a maintenance schedule.	1a
Three-year maintenance is more effective than one year to prevent recurrence in patients with high-risk tumours, but not in patients with intermediate-risk tumours.	1a



### 7.2.3 **Combination therapy**

In one RCT, a combination of MMC and BCG was shown to be more effective in reducing recurrences but more toxic compared to BCG monotherapy (LE: 1b). Using similar BCG schedules in both groups, each BCG instillation in the combination group was preceded a day before by one MMC instillation [234]. In a Cochrane meta-analysis of 4 RCTs including NMIBC at high risk of recurrence and progression, a combination of BCG + IFN 2 $\alpha$  did not show a clear difference in recurrence and progression over BCG alone. In one study, weekly MMC followed by monthly BCG alternating with IFN 2 $\alpha$  showed a higher probability of recurrence compared to MMC followed by BCG alone [235]. Additionally, a recent RCT in a similar population of NMIBC comparing BCG monotherapy with a combination of epirubicin and interferon for up to two years showed the latter was significantly inferior to BCG monotherapy in preventing recurrence [236] (LE: 1b). In an RCT using MMC with EMDA, a combination of BCG and MMC with EMDA showed an improved recurrence-free interval and reduced progression rate compared to BCG monotherapy [201, 237] (LE: 2).

### 7.2.4 **Specific aspects of treatment of Carcinoma in situ**

#### 7.2.4.1 **Treatment strategy**

The detection of concurrent CIS increases the risk of recurrence and progression of TaT1 tumours [151, 153], in this case further treatment according to the criteria summarised in Sections 7.2.1, 7.2.2, 7.3 and 7.4 is mandatory. Carcinoma *in situ* cannot be cured by an endoscopic procedure alone. Histological diagnosis of CIS must be followed by further treatment, either intravesical BCG instillations or RC (LE: 4). Tumour-specific-survival rates after immediate RC for CIS are excellent, but as many as 40-50% of patients might be over treated [161] (LE: 3).

#### 7.2.4.2 **Cohort studies on intravesical BCG or chemotherapy**

In retrospective evaluations of patients with CIS, a complete response rate of 48% was achieved with intravesical chemotherapy and 72-93% with BCG [161-164, 238] (LE: 2a). Up to 50% of complete responders might eventually show recurrence with a risk of invasion and/or extravesical recurrence [164, 227, 238, 239] (LE: 3).

#### 7.2.4.3 **Prospective randomised trials on intravesical BCG or chemotherapy**

Unfortunately, there have been few randomised trials in patients with CIS only. A meta-analysis of clinical trials comparing intravesical BCG to intravesical chemotherapy in patients with CIS has shown a significantly increased response rate after BCG and a reduction of 59% in the odds of treatment failure with BCG [240] (LE: 1a).

In an EORTC-GUCG meta-analysis of tumour progression, in a subgroup of 403 patients with CIS, BCG reduced the risk of progression by 35% as compared to intravesical chemotherapy or different immunotherapy [188] (LE: 1b). The combination of BCG and MMC was not superior to BCG alone [241]. In summary, compared to chemotherapy, BCG treatment of CIS increases the complete response rate, the overall percentage of patients who remain disease free, and reduces the risk of tumour progression (LE: 1b).

#### 7.2.4.4 **Treatment of CIS in prostatic urethra and upper urinary tract**


Patients with CIS are at high risk of extravesical involvement in the UUT and in the prostatic urethra. Solsona *et al.* found that 63% of 138 patients with CIS developed extravesical involvement initially or during follow-up [242]. Patients with extravesical involvement had worse survival than those with bladder CIS alone [242] (LE: 3). In the prostate, CIS might be present only in the epithelial lining of the prostatic urethra or in the prostatic ducts [37]. These situations should be distinguished from tumour invasion into the prostatic stroma (stage T4a in bladder tumours), and for which immediate radical cystoprostatectomy is mandatory. Patients with CIS in the epithelial lining of the prostatic urethra can be treated by intravesical instillation of BCG. Transurethral resection of the prostate can improve contact of BCG with the prostatic urethra [100, 243] (LE: 3). However, potential spread of CIS has to be considered; no suprapubic trocar-placed catheter should be used.

In patients with prostatic duct involvement, there are promising results of BCG, but only from small series. The data are insufficient to provide clear treatment recommendations and radical surgery should be considered [243, 244] (LE: 3). Treatment of CIS that involves the UUT is discussed in the EAU Guidelines on Urothelial Tumours of the Upper Urinary Tract [1].

#### 7.2.4.5 **Summary of evidence – treatment of carcinoma in situ**

Summary of evidence	LE
Carcinoma <i>in situ</i> (CIS) cannot be cured by an endoscopic procedure alone.	4
Compared to intravesical chemotherapy, bacillus Calmette-Guérin treatment of CIS increases the complete response rate, the overall percentage of patients who remain disease free, and reduces the risk of tumour progression.	1b

**Flowchart 7.1: Treatment strategy in primary or recurrent tumour(s) without previous BCG\***



\*For details and explanations see the text of the guidelines

BCG = bacillus Calmette-Guérin; CIS = carcinoma in situ; MIBC = muscle-invasive bladder cancer; PDD = photodynamic diagnosis; TURB = transurethral resection of the bladder.

### 7.3 Treatment of failure of intravesical therapy

#### 7.3.1 Failure of intravesical chemotherapy

Patients with NMIBC recurrence after a chemotherapy regimen can benefit from BCG instillations. Prior intravesical chemotherapy has no impact on the effect of BCG instillation [189] (LE: 1a).

#### 7.3.2 Recurrence and failure after intravesical bacillus Calmette-Guérin (BCG) immunotherapy

Categories of unsuccessful treatment with intravesical BCG are presented in Table 7.2.

**Table 7.2: Categories of unsuccessful treatment with intravesical BCG**

<b>BCG failure</b>
Whenever a MIBC is detected during follow-up.
BCG-refractory tumour: 1. If high-grade, non-muscle-invasive papillary tumour is present at three months [245]. Further conservative treatment with BCG is associated with increased risk of progression [165, 246] (LE: 3). 2. If CIS (without concomitant papillary tumour) is present at both three and six months. If patients with CIS present at three months, an additional BCG course can achieve a complete response in > 50% of cases [37] (LE: 3). 3. If high-grade tumour appears during BCG therapy*.
High-grade recurrence after BCG. Recurrence of high-grade/grade 3 (WHO 2004/1973) tumour after completion of BCG maintenance, despite an initial response [247] (LE: 3).
<b>BCG intolerance</b>
Severe side effects that prevent further BCG instillation before completing treatment [222].

\* Patients with low-grade recurrence during or after BCG treatment are not considered to be a BCG failure.

#### 7.3.3 Treatment of BCG failure and recurrences after BCG

Treatment recommendations and options are provided in Sections 7.5 and 7.7. They reflect the categories mentioned in Table 7.2 and tumour characteristics at the time of recurrence.

Patients with BCG failure are unlikely to respond to further BCG therapy; RC is therefore the preferred option. Various studies suggest that repeat BCG therapy is appropriate for non-high-grade and even for some high-grade recurrent tumours [248, 249] (LE: 3). Additionally, there are now several bladder preservation strategies available that can be categorised as intravesical immunotherapy [250], intravesical chemotherapy, device-assisted therapy (see Section 7.2.1.3.2), and combination therapy (see Section 7.2.3) [251]. Changing from BCG to these options can yield responses in selected cases with BCG treatment failure [248, 250-258] (LE: 3).

Treatments other than RC must be considered oncologically inferior in patients with BCG failure at the present time [165, 245, 246] (LE: 3).


Little is known about the optimal treatment in patients with high-risk tumours who could not complete BCG instillations because of intolerance.

Non-high-grade recurrence after BCG is not considered as BCG failure. Treatment decision should be individualised according to tumour characteristics. It could include chemotherapy or repeat BCG instillations, but the published evidence is very low.

#### 7.3.4 Summary of evidence - treatment failure of intravesical therapy

Summary of evidence	LE
Prior intravesical chemotherapy has no impact on the effect of bacillus Calmette-Guérin (BCG) instillation.	1a
Treatments other than radical cystectomy must be considered oncologically inferior in patients with BCG failure.	3

**Flowchart 7.2: Treatment strategy in recurrence during or after intravesical BCG\***



BCG = bacillus Calmette-Guérin; CIS = carcinoma in situ; HG = high-grade; IVU = intravenous urography; LG = low-grade; PDD = photodynamic diagnosis; TURB = transurethral resection of the bladder.

#### 7.4 Radical cystectomy for NMIBC

There are several reasons to consider immediate RC for selected patients with NMIBC:

- The staging accuracy for T1 tumours by TURB is low with 27-51% of patients being upstaged to muscle-invasive tumour at RC [122, 142, 259-262] (LE: 3).
- Some patients with NMIBC experience disease progression to muscle-invasive disease (Table 6.2).
- Patients who experience disease progression to muscle-invasive stage, have a worse prognosis than those who present with 'primary' muscle-invasive disease [263, 264].

The potential benefit of RC must be weighed against its risks, morbidity, and impact on quality of life. It is reasonable to propose immediate RC in those patients with NMIBC who are at highest risk of disease progression (see Section 7.6) [56, 120, 151, 153, 265] (LE: 3).

The benefits and risks of immediate and delayed RC should be discussed with patients, in a shared decision-making process. Individual additional prognostic factors in T1 tumours mentioned in Sections 4.7 and 6.4 should be considered. Early RC is strongly recommended in patients with BCG-refractory tumours, as mentioned above. A delay in RC may lead to decreased disease-specific survival [266] (LE: 3). In patients in whom RC is performed before progression to MIBC, the five-year disease-free survival rate exceeds 80% [267-269] (LE: 3).

## 7.5 Guidelines for adjuvant therapy in TaT1 tumours and for therapy of carcinoma *in situ*

General recommendations	Strength rating
Counsel smokers with confirmed non-muscle-invasive bladder cancer (NMIBC) to stop smoking.	Strong
The type of further therapy after transurethral resection of the bladder (TURB) should be based on the risk groups shown in Table 6.3 and Section 7.6.	Strong
In patients with tumours presumed to be at low risk and in those presumed to be at intermediate risk with previous low recurrence rate ( $\leq$ one recurrence per year) and expected EORTC recurrence score $< 5$ , one immediate chemotherapy instillation is recommended.	Strong
In patients with intermediate-risk tumours (with or without immediate instillation), one-year full-dose bacillus Calmette-Guérin (BCG) treatment (induction plus three-weekly instillations at 3, 6 and 12 months), or instillations of chemotherapy (the optimal schedule is not known) for a maximum of one year is recommended. The final choice should reflect the individual patient's risk of recurrence and progression as well as the efficacy and side effects of each treatment modality.	Strong
In patients with high-risk tumours, full-dose intravesical BCG for one to three years (induction plus three-weekly instillations at 3, 6, 12, 18, 24, 30 and 36 months), is indicated. The additional beneficial effect of the second and third years of maintenance should be weighed against its added costs and inconveniences.	Strong
Offer transurethral resection of the prostate, followed by intravesical instillation of BCG to patients with CIS in the epithelial lining of the prostatic urethra.	Weak
Discuss immediate radical cystectomy with patients at highest risk of tumour progression (see Section 7.6).	Strong
Perform a radical cystectomy (RC) to patients with BCG failure (see Section 7.7).	Strong
In patients with BCG-refractory tumours, who are not candidates for RC due to comorbidities, use preservation strategies (intravesical chemotherapy, chemotherapy and microwave-induced hyperthermia).	Weak
<b>Recommendations – technical aspects for treatment</b>	
<b><i>Intravesical chemotherapy</i></b>	
If given, administer a single immediate instillation of chemotherapy within 24 hours after TURB.	Weak
Omit a single immediate instillation of chemotherapy in any case of overt or suspected bladder perforation or bleeding requiring bladder irrigation.	Strong
Give clear instructions to the nursing staff to control the free flow of the bladder catheter at the end of the immediate instillation.	Strong
The optimal schedule and duration of further intravesical chemotherapy instillation is not defined; however, it should not exceed one year.	Weak
If intravesical chemotherapy is given, it is advised to use the drug at its optimal pH and to maintain the concentration of the drug by reducing fluid intake before and during instillation.	Strong
The length of individual instillation should be one to two hours.	Weak
<b><i>BCG intravesical immunotherapy</i></b>	
Absolute contraindications of BCG intravesical instillation are: <ul style="list-style-type: none"> <li>• during the first two weeks after TURB;</li> <li>• in patients with visible haematuria;</li> <li>• after traumatic catheterisation;</li> <li>• in patients with symptomatic urinary tract infection.</li> </ul>	Strong

## 7.6 Treatment recommendations in TaT1 tumours and carcinoma *in situ* according to risk stratification

Risk category	Definition	Treatment recommendation
<b>Low-risk tumours</b>	Primary, solitary, TaG1 (PUNLMP, LG), < 3 cm, no CIS	One immediate instillation of intravesical chemotherapy after TURB.
<b>Intermediate-risk tumours</b>	All tumours not defined in the two adjacent categories (between the category of low and high risk).	In patients with previous low recurrence rate (less than or equal to one recurrence per year) and expected EORTC recurrence score < 5, one immediate instillation of intravesical chemotherapy after TURB. In all patients either one-year full-dose BCG treatment (induction plus three-weekly instillations at three, six and twelve months), or instillations of chemotherapy (the optimal schedule is not known) for a maximum of one year.
<b>High-risk tumours</b>	Any of the following: <ul style="list-style-type: none"> <li>• T1 tumours;</li> <li>• G3 (HG) tumour;</li> <li>• CIS;</li> <li>• Multiple, recurrent and large (&gt; 3 cm) TaG1G2/LG tumours (all features must be present).</li> </ul>	Intravesical full-dose BCG instillations for one to three years or radical cystectomy (in highest-risk tumours - <i>see below</i> ).
	<b>Subgroup of highest-risk tumours</b>	
	T1G3/HG associated with concurrent bladder CIS, multiple and/or large T1G3/HG and/or recurrent T1G3/HG, T1G3/HG with CIS in the prostatic urethra, some forms of variant histology of urothelial carcinoma, LVI (see Sections 4.7 and 6.4).	Radical cystectomy should be considered.  In those who refuse or are unfit for RC intravesical full-dose BCG instillations for one to three years.
	BCG-refractory tumours.	Radical cystectomy is recommended.

## 7.7 Treatment options for bacillus Calmette-Guérin (BCG) failure and recurrences after BCG

Category	Treatment options
BCG-refractory tumour	1. Radical cystectomy 2. Bladder-preserving strategies in patients unsuitable for radical cystectomy
High-grade (HG) recurrence after BCG	1. Radical cystectomy 2. Bladder-preserving strategies 3. Repeat BCG course
Non-HG recurrence after BCG for primary intermediate-risk tumour	1. Repeat BCG or intravesical chemotherapy 2. Radical cystectomy

# 8. FOLLOW-UP OF PATIENTS WITH NMIBC

As a result of the risk of recurrence and progression, patients with NMIBC need surveillance, following therapy. However, the frequency and duration of cystoscopy and imaging should reflect the individual patient's degree of risk. Using risk tables (see Tables 6.1 and 6.2), the short- and long-term risks of recurrence and progression in individual patients may be predicted and the follow-up schedule adapted accordingly [151, 153].

When planning the follow-up schedule and methods, the following aspects should be considered:

- The prompt detection of muscle-invasive and HG/G3 non-muscle-invasive recurrence is crucial because a delay in diagnosis and therapy can be life-threatening.

- Tumour recurrence in the low-risk group is nearly always low stage and LG/G1. Small, TaLG/G1 papillary recurrence does not present an immediate danger to the patient and early detection is not essential for successful therapy [270, 271] (LE: 2b). Fulguration of small papillary recurrences on an outpatient basis could be a safe option that reduces the therapeutic burden [114] (LE: 3). Multiple authors have even suggested temporary surveillance in selected cases [272-274] (LE: 3/2a).
- The first cystoscopy after TURB at three months is an important prognostic indicator for recurrence and progression [159, 165, 275-277] (LE: 1a). Therefore, the first cystoscopy should always be performed three months after TURB in all patients with TaT1 tumours and CIS.
- In tumours at low risk, the risk of recurrence after five recurrence-free years is low [276] (LE: 3).
- Discontinuation of cystoscopy or its replacement with less-invasive methods can be considered [277].
- In tumours originally intermediate- or high risk, recurrences after ten years tumour-free are not unusual [278] (LE: 3). Therefore, life-long follow-up is recommended [277].
- The follow-up strategy must reflect the risk of extravesical recurrence (prostatic urethra in men and UUT in both genders).
- The risk of UUT recurrence increases in patients with multiple- and high-risk tumours [68] (LE: 3).
- Positive urine test results have a positive impact on the quality of follow-up cystoscopy [97] (LE: 1b) supporting the adjunctive role of urine tests during follow-up.
- In patients initially diagnosed with TaLG/G1-2 BC, US of the bladder may be a mode of surveillance in case cystoscopy is not possible or refused by the patient [279].

No non-invasive method can replace endoscopy. Follow-up is therefore based on regular cystoscopy (see Section 5.7). There is a lack of randomised studies investigating the possibility of safely reducing the frequency of follow-up cystoscopy.

As CIS is often not visible, multiple biopsies may be necessary in selected cases to confirm the efficacy of intravesical treatment in patients treated for CIS [98]. The recommendations for follow-up are mainly based on retrospective data (see Section 8.1).

## 8.1 Summary of evidence and guidelines for follow-up of patients after transurethral resection of the bladder for non-muscle-invasive bladder cancer

Summary of evidence	LE
The first cystoscopy after transurethral resection of the bladder at 3 months is an important prognostic indicator for recurrence and progression.	1a
The risk of upper urinary tract (UUT) recurrence increases in patients with multiple- and high-risk tumours.	3

Recommendations	Strength rating
Base follow-up of TaT1 tumours and carcinoma <i>in situ</i> (CIS) on regular cystoscopy.	Strong
Patients with low-risk Ta tumours should undergo cystoscopy at three months. If negative, subsequent cystoscopy is advised nine months later, and then yearly for five years.	Weak
Patients with high-risk tumours should undergo cystoscopy and urinary cytology at three months. If negative, subsequent cystoscopy and cytology should be repeated every three months for a period of two years, and every six months thereafter until five years, and then yearly.	Weak
Patients with intermediate-risk Ta tumours should have an in-between (individualised) follow-up scheme using cystoscopy.	Weak
Regular (yearly) upper tract imaging (computed tomography-intravenous urography [CT-IVU] or IVU) is recommended for high-risk tumours.	Weak
Endoscopy under anaesthesia and bladder biopsies should be performed when office cystoscopy shows suspicious findings or if urinary cytology is positive.	Strong
Consider random (R)-biopsies or photodynamic diagnosis (PDD)-guided biopsies after intravesical treatment (at three or six months) in patients with CIS.	Weak
During follow-up in patients with positive cytology and no visible tumour in the bladder, R-biopsies or PDD-guided biopsies (if equipment is available) and investigation of extravesical locations (CT urography, prostatic urethra biopsy) are recommended.	Strong
In patients initially diagnosed with TaLG/G1-2 bladder cancer, use ultrasound of the bladder during surveillance in case cystoscopy is not possible or refused by the patient.	Weak

## 9. REFERENCES

1. Roupřet, M., *et al.*, EAU Guidelines on Urothelial Carcinomas of the Upper Urinary Tract. EAU Guidelines 2018, Edn. presented at the 33rd EAU Annual Congress. European Association of Urology, Arnhem, The Netherlands.
2. Witjes, J., *et al.*, EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. EAU Guidelines 2018, Edn. presented at the 33rd EAU Annual Congress. European Association of Urology, Arnhem, The Netherlands.
3. Gakis, G., *et al.*, EAU Guidelines on Primary Urethral Carcinoma, EAU Guidelines 2018, Edn. presented at the 33rd EAU Annual Congress. European Association of Urology, Arnhem, The Netherlands.
4. Babjuk, M., *et al.* EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. *Eur Urol*, 2017. 71: 447.  
<https://www.ncbi.nlm.nih.gov/pubmed/27324428>
5. Phillips, B. Oxford Centre for Evidence-based Medicine Levels of Evidence. Updated by Jeremy Howick March 2009. 1998.  
<http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/>
6. Guyatt, G.H., *et al.* What is “quality of evidence” and why is it important to clinicians? *BMJ*, 2008. 336: 995.  
<https://www.ncbi.nlm.nih.gov/pubmed/18456631>
7. Guyatt, G.H., *et al.* GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ*, 2008. 336: 924.  
<https://www.ncbi.nlm.nih.gov/pubmed/18436948>
8. Soukup, V., *et al.* Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review. *Eur Urol*, 2017. 72: 801.  
<https://www.ncbi.nlm.nih.gov/pubmed/28457661>
9. Ferlay J., *et al.* GLOBOCAN 2012 v1.0: Estimated cancer incidence, mortality and prevalence worldwide in 2012. 2013. 2015.  
<http://globocan.iarc.fr/Default.aspx>
10. Burger, M., *et al.* Epidemiology and risk factors of urothelial bladder cancer. *Eur Urol*, 2013. 63: 234.  
<https://www.ncbi.nlm.nih.gov/pubmed/22877502>
11. Chavan, S., *et al.* International variations in bladder cancer incidence and mortality. *Eur Urol*, 2014. 66: 59.  
<https://www.ncbi.nlm.nih.gov/pubmed/24451595>
12. Comperat, E., *et al.* Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years old. *Virchows Arch*, 2015. 466: 589.  
<https://www.ncbi.nlm.nih.gov/pubmed/25697540>
13. Freedman, N.D., *et al.* Association between smoking and risk of bladder cancer among men and women. *JAMA*, 2011. 306: 737.  
<https://www.ncbi.nlm.nih.gov/pubmed/21846855>
14. van Osch, F.H., *et al.* Quantified relations between exposure to tobacco smoking and bladder cancer risk: a meta-analysis of 89 observational studies. *Int J Epidemiol*, 2016. 45: 857.  
<https://www.ncbi.nlm.nih.gov/pubmed/27097748>
15. Colt, J.S., *et al.* A case-control study of occupational exposure to metalworking fluids and bladder cancer risk among men. *Occup Environ Med*, 2014. 71: 667.  
<https://www.ncbi.nlm.nih.gov/pubmed/25201311>
16. Pesch, B., *et al.* Screening for bladder cancer with urinary tumor markers in chemical workers with exposure to aromatic amines. *Int Arch Occup Environ Health*, 2013.  
<https://www.ncbi.nlm.nih.gov/pubmed/24129706>
17. Egbers, L., *et al.* The prognostic value of family history among patients with urinary bladder cancer. *Int J Cancer*, 2015. 136: 1117.  
<https://www.ncbi.nlm.nih.gov/pubmed/24978702>
18. Corral, R., *et al.* Comprehensive analyses of DNA repair pathways, smoking and bladder cancer risk in Los Angeles and Shanghai. *Int J Cancer*, 2014. 135: 335.  
<https://www.ncbi.nlm.nih.gov/pubmed/24382701>
19. Figueroa, J.D., *et al.* Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with bladder cancer risk in individuals of European ancestry. *Hum Mol Genet*, 2016. 25: 1203.  
<https://www.ncbi.nlm.nih.gov/pubmed/26732427>



20. Wu, J., *et al.* A Functional rs353293 Polymorphism in the Promoter of miR-143/145 Is Associated with a Reduced Risk of Bladder Cancer. *PLoS One*, 2016. 11: e0159115.  
<https://www.ncbi.nlm.nih.gov/pubmed/27438131>
21. Zhong, J.H., *et al.* Association between APE1 Asp148Glu polymorphism and the risk of urinary cancers: a meta-analysis of 18 case-control studies. *Onco Targets Ther*, 2016. 9: 1499.  
<https://www.ncbi.nlm.nih.gov/pubmed/27042118>
22. Al-Zalabani, A.H., *et al.* Modifiable risk factors for the prevention of bladder cancer: a systematic review of meta-analyses. *Eur J Epidemiol*, 2016. 31: 811.  
<https://www.ncbi.nlm.nih.gov/pubmed/27000312>
23. Steinmaus, C., *et al.* Increased lung and bladder cancer incidence in adults after in utero and early-life arsenic exposure. *Cancer Epidemiol Biomarkers Prev*, 2014. 23: 1529.  
<https://www.ncbi.nlm.nih.gov/pubmed/24859871>
24. Buckland, G., *et al.* Adherence to the Mediterranean diet and risk of bladder cancer in the EPIC cohort study. *Int J Cancer*, 2014. 134: 2504.  
<https://www.ncbi.nlm.nih.gov/pubmed/24226765>
25. Liu, H., *et al.* Fruit and vegetable consumption and risk of bladder cancer: an updated meta-analysis of observational studies. *Eur J Cancer Prev*, 2015. 24: 508.  
<https://www.ncbi.nlm.nih.gov/pubmed/25642791>
26. Vieira, A.R., *et al.* Fruits, vegetables, and bladder cancer risk: a systematic review and meta-analysis. *Cancer Med*, 2015. 4: 136.  
<https://www.ncbi.nlm.nih.gov/pubmed/25461441>
27. Zhao, L., *et al.* Association of body mass index with bladder cancer risk: a dose-response meta-analysis of prospective cohort studies. *Oncotarget*, 2017. 8: 33990.  
<https://www.ncbi.nlm.nih.gov/pubmed/28389625>
28. Tuccori, M., *et al.* Pioglitazone use and risk of bladder cancer: population based cohort study. *BMJ*, 2016. 352: i1541.  
<https://www.ncbi.nlm.nih.gov/pubmed/27029385>
29. Sobin LH, G.M., Wittekind C., *et al.* TNM classification of malignant tumors. UICC International Union Against Cancer. 7th edn. 2009, Wiley-Blackwell.  
<http://www.uicc.org/tnm/>
30. Otto, W., *et al.* WHO 1973 grade 3 and infiltrative growth pattern proved, aberrant E-cadherin expression tends to be of predictive value for progression in a series of stage T1 high-grade bladder cancer after organ-sparing approach. *Int Urol Nephrol*, 2017. 49: 431.  
<https://www.ncbi.nlm.nih.gov/pubmed/28035618>
31. van Rhijn, B.W., *et al.* A new and highly prognostic system to discern T1 bladder cancer substage. *Eur Urol*, 2012. 61: 378.  
<https://www.ncbi.nlm.nih.gov/pubmed/22036775>
32. Moch, H., *et al.*, WHO Classification of Tumours of the Urinary System and Male Genital Organs. 4th ed. ed, ed. O. H. 2016, Lyon, France  
<http://apps.who.int/bookorders/anglais/detart1.jsp?codlan=1&codcol=70&codcch=4008>
33. Colombo, R., *et al.* Feasibility and Clinical Roles of Different Substaging Systems at First and Second Transurethral Resection in Patients with T1 High-Grade Bladder Cancer. *Eur Urol Focus*, 2016 [prior to print].  
<https://www.ncbi.nlm.nih.gov/pubmed/28753746>
34. Sauter G, *et al.* Tumours of the urinary system: non-invasive urothelial neoplasias. In: WHO classification of classification of tumours of the urinary system and male genital organs., Sauter G, Amin M, *et al.*, Eds. 2004, IARCC Press: Lyon.  
<http://publications.iarc.fr/Book-And-Report-Series/Who-Iarc-Classification-Of-Tumours/Who-Classification-Of-Tumours-Of-The-Urinary-System-And-Male-Genital-Organs-2016>
35. Epstein, J.I., *et al.* The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. *Am J Surg Pathol*, 1998. 22: 1435.  
<https://www.ncbi.nlm.nih.gov/pubmed/9850170>
36. MacLennan, G.T., *et al.* Histologic grading of noninvasive papillary urothelial neoplasms. *Eur Urol*, 2007. 51: 889.  
<https://www.ncbi.nlm.nih.gov/pubmed/17095142>
37. Sylvester, R.J., *et al.* High-grade Ta urothelial carcinoma and carcinoma *in situ* of the bladder. *Urology*, 2005. 66: 90.  
<https://www.ncbi.nlm.nih.gov/pubmed/16399418>

38. Lamm, D., *et al.* Updated concepts and treatment of carcinoma *in situ*. *Urol Oncol*, 1998. 4: 130.  
<https://www.ncbi.nlm.nih.gov/pubmed/21227218>
39. Witjes, J.A., *et al.* Review pathology in a diagnostic bladder cancer trial: effect of patient risk category. *Urology*, 2006. 67: 751.  
<https://www.ncbi.nlm.nih.gov/pubmed/16566990>
40. May, M., *et al.* Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: a multicentre study comparing the 1973 and 2004 World Health Organisation classifications. *Eur Urol*, 2010. 57: 850.  
<https://www.ncbi.nlm.nih.gov/pubmed/19346063>
41. van Rhijn, B.W., *et al.* Pathological stage review is indicated in primary pT1 bladder cancer. *BJU Int*, 2010. 106: 206.  
<https://www.ncbi.nlm.nih.gov/pubmed/20002439>
42. Comperat, E., *et al.* An interobserver reproducibility study on invasiveness of bladder cancer using virtual microscopy and heatmaps. *Histopathology*, 2013. 63: 756.  
<https://www.ncbi.nlm.nih.gov/pubmed/24102813>
43. Mangrud, O.M., *et al.* Reproducibility and prognostic value of WHO1973 and WHO2004 grading systems in TaT1 urothelial carcinoma of the urinary bladder. *PLoS One*, 2014. 9: e83192.  
<https://www.ncbi.nlm.nih.gov/pubmed/>
44. van Rhijn, B.W., *et al.* The pathologist's mean grade is constant and individualizes the prognostic value of bladder cancer grading. *Eur Urol*, 2010. 57: 1052.  
<https://www.ncbi.nlm.nih.gov/pubmed/24409280>
45. Luchey, A.M., *et al.* Change in Management Based on Pathologic Second Opinion Among Bladder Cancer Patients Presenting to a Comprehensive Cancer Center: Implications for Clinical Practice. *Urology*, 2016. 93: 130.  
<https://www.ncbi.nlm.nih.gov/pubmed/27041469>
46. Kim, H.S., *et al.* Presence of lymphovascular invasion in urothelial bladder cancer specimens after transurethral resections correlates with risk of upstaging and survival: a systematic review and meta-analysis. *Urol Oncol*, 2014. 32: 1191.  
<https://www.ncbi.nlm.nih.gov/pubmed/24954108>
47. Tilki, D., *et al.* Lymphovascular invasion is independently associated with bladder cancer recurrence and survival in patients with final stage T1 disease and negative lymph nodes after radical cystectomy. *BJU Int*, 2013. 111: 1215.  
<https://www.ncbi.nlm.nih.gov/pubmed/23181623>
48. Martin-Doyle, W., *et al.* Improving selection criteria for early cystectomy in high-grade t1 bladder cancer: a meta-analysis of 15,215 patients. *J Clin Oncol*, 2015. 33: 643.  
<https://www.ncbi.nlm.nih.gov/pubmed/25559810>
49. Comperat, E., *et al.* Micropapillary urothelial carcinoma of the urinary bladder: a clinicopathological analysis of 72 cases. *Pathology*, 2010. 42: 650.  
<https://www.ncbi.nlm.nih.gov/pubmed/21080874>
50. Kaimakliotis, H.Z., *et al.* Plasmacytoid variant urothelial bladder cancer: is it time to update the treatment paradigm? *Urol Oncol*, 2014. 32: 833.  
<https://www.ncbi.nlm.nih.gov/pubmed/24954925>
51. Willis, D.L., *et al.* Micropapillary bladder cancer: current treatment patterns and review of the literature. *Urol Oncol*, 2014. 32: 826.  
<https://www.ncbi.nlm.nih.gov/pubmed/24931270>
52. Beltran, A.L., *et al.* Clinicopathological characteristics and outcome of nested carcinoma of the urinary bladder. *Virchows Arch*, 2014. 465: 199.  
<https://www.ncbi.nlm.nih.gov/pubmed/24878757>
53. Soave, A., *et al.* Does the extent of variant histology affect oncological outcomes in patients with urothelial carcinoma of the bladder treated with radical cystectomy? *Urol Oncol*, 2015. 33: 21 e1.  
<https://www.ncbi.nlm.nih.gov/pubmed/25465301>
54. Masson-Lecomte, A., *et al.* Oncological outcomes of advanced muscle-invasive bladder cancer with a micropapillary variant after radical cystectomy and adjuvant platinum-based chemotherapy. *World J Urol*, 2015. 33: 1087.  
<https://www.ncbi.nlm.nih.gov/pubmed/25179011>
55. Seisen, T., *et al.* Impact of histological variants on the outcomes of nonmuscle invasive bladder cancer after transurethral resection. *Curr Opin Urol*, 2014. 24: 524.  
<https://www.ncbi.nlm.nih.gov/pubmed/25051021>
56. Willis, D.L., *et al.* Clinical outcomes of cT1 micropapillary bladder cancer. *J Urol*, 2015. 193: 1129.  
<https://www.ncbi.nlm.nih.gov/pubmed/25254936>

57. Burger, M., *et al.* Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study. *Eur Urol*, 2008. 54: 835.  
<https://www.ncbi.nlm.nih.gov/pubmed/18166262>
58. Frstrup, N., *et al.* Cathepsin E, maspin, Plk1, and survivin are promising prognostic protein markers for progression in non-muscle invasive bladder cancer. *Am J Pathol*, 2012. 180: 1824.  
<https://www.ncbi.nlm.nih.gov/pubmed/22449953>
59. Palou, J., *et al.* Protein expression patterns of ezrin are predictors of progression in T1G3 bladder tumours treated with nonmaintenance bacillus Calmette-Guerin. *Eur Urol*, 2009. 56: 829.  
<https://www.ncbi.nlm.nih.gov/pubmed/18926620>
60. van Rhijn, B.W., *et al.* The FGFR3 mutation is related to favorable pT1 bladder cancer. *J Urol*, 2012. 187: 310.  
<https://www.ncbi.nlm.nih.gov/pubmed/22099989>
61. Remy, E., *et al.* A Modeling Approach to Explain Mutually Exclusive and Co-Occurring Genetic Alterations in Bladder Tumorigenesis. *Cancer Res*, 2015. 75: 4042.  
<https://www.ncbi.nlm.nih.gov/pubmed/26238783>
62. Ramirez, D., *et al.* Microscopic haematuria at time of diagnosis is associated with lower disease stage in patients with newly diagnosed bladder cancer. *BJU Int*, 2016. 117: 783.  
<https://www.ncbi.nlm.nih.gov/pubmed/26435378>
63. Choyke, P.L. Radiologic evaluation of hematuria: guidelines from the American College of Radiology's appropriateness criteria. *Am Fam Physician*, 2008. 78: 347.  
<https://www.ncbi.nlm.nih.gov/pubmed/18711950>
64. Nolte-Ernsting, C., *et al.* Understanding multislice CT urography techniques: Many roads lead to Rome. *Eur Radiol*, 2006. 16: 2670.  
<https://www.ncbi.nlm.nih.gov/pubmed/16953373>
65. Goessl, C., *et al.* Is routine excretory urography necessary at first diagnosis of bladder cancer? *J Urol*, 1997. 157: 480.  
<https://www.ncbi.nlm.nih.gov/pubmed/8996338>
66. Palou, J., *et al.* Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumor. *J Urol*, 2005. 174: 859.  
<https://www.ncbi.nlm.nih.gov/pubmed/16093970>
67. Holmang, S., *et al.* Long-term followup of a bladder carcinoma cohort: routine followup urography is not necessary. *J Urol*, 1998. 160: 45.  
<https://www.ncbi.nlm.nih.gov/pubmed/9628602>
68. Millan-Rodriguez, F., *et al.* Upper urinary tract tumors after primary superficial bladder tumors: prognostic factors and risk groups. *J Urol*, 2000. 164: 1183.  
<https://www.ncbi.nlm.nih.gov/pubmed/10992362>
69. Hilton, S., *et al.* Recent advances in imaging cancer of the kidney and urinary tract. *Surg Oncol Clin N Am*, 2014. 23: 863.  
<https://www.ncbi.nlm.nih.gov/pubmed/25246053>
70. Yafi, F.A., *et al.* Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer. *Urol Oncol*, 2015. 33: 66 e25.  
<https://www.ncbi.nlm.nih.gov/pubmed/25037483>
71. Tetu, B. Diagnosis of urothelial carcinoma from urine. *Mod Pathol*, 2009. 22 Suppl 2: S53.  
<https://www.ncbi.nlm.nih.gov/pubmed/19494853>
72. Raitanen, M.P., *et al.* Differences between local and review urinary cytology in diagnosis of bladder cancer. An interobserver multicenter analysis. *Eur Urol*, 2002. 41: 284.  
<https://www.ncbi.nlm.nih.gov/pubmed/12180229>
73. Rosenthal DL., *et al.*, The Paris System for Reporting Urinary Cytology. 2016, Switzerland.  
<http://www.springer.com/us/book/9783319228631>
74. Burton, J.L., *et al.* Demand management in urine cytology: a single cytospin slide is sufficient. *J Clin Pathol*, 2000. 53: 718.  
<https://www.ncbi.nlm.nih.gov/pubmed/11041065>
75. Nabi, G., *et al.* Suspicious urinary cytology with negative evaluation for malignancy in the diagnostic investigation of haematuria: how to follow up? *J Clin Pathol*, 2004. 57: 365.  
<https://www.ncbi.nlm.nih.gov/pubmed/15047737>
76. Lokeshwar, V.B., *et al.* Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. *Urology*, 2005. 66: 35.  
<https://www.ncbi.nlm.nih.gov/pubmed/16399415>

77. Glas, A.S., *et al.* Tumor markers in the diagnosis of primary bladder cancer. A systematic review. *J Urol*, 2003. 169: 1975.  
<https://www.ncbi.nlm.nih.gov/pubmed/12771702>
78. van Rhijn, B.W., *et al.* Urine markers for bladder cancer surveillance: a systematic review. *Eur Urol*, 2005. 47: 736.  
<https://www.ncbi.nlm.nih.gov/pubmed/15925067>
79. Lotan, Y., *et al.* Considerations on implementing diagnostic markers into clinical decision making in bladder cancer. *Urol Oncol*, 2010. 28: 441.  
<https://www.ncbi.nlm.nih.gov/pubmed/20610281>
80. Hajdinjak, T. UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing. *Urol Oncol*, 2008. 26: 646.  
<https://www.ncbi.nlm.nih.gov/pubmed/18367109>
81. Schlomer, B.J., *et al.* Prospective validation of the clinical usefulness of reflex fluorescence *in situ* hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder. *J Urol*, 2010. 183: 62.  
<https://www.ncbi.nlm.nih.gov/pubmed/19913822>
82. Kamat, A.M., *et al.* Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity. *BJU Int*, 2011. 108: 1119.  
<https://www.ncbi.nlm.nih.gov/pubmed/21426474>
83. Kavalieris, L., *et al.* Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter Study. *J Urol*, 2017. 197: 1419.  
<https://www.ncbi.nlm.nih.gov/pubmed/27986532>
84. Beukers, W., *et al.* FGFR3, TERT and OTX1 as a Urinary Biomarker Combination for Surveillance of Patients with Bladder Cancer in a Large Prospective Multicenter Study. *J Urol*, 2017. 197: 1410.  
<https://www.ncbi.nlm.nih.gov/pubmed/28049011>
85. Ribal, M.J., *et al.* Gene expression test for the non-invasive diagnosis of bladder cancer: A prospective, blinded, international and multicenter validation study. *Eur J Cancer*, 2016. 54: 131.  
<https://www.ncbi.nlm.nih.gov/pubmed/26761785>
86. Critelli, R., *et al.* Detection of multiple mutations in urinary exfoliated cells from male bladder cancer patients at diagnosis and during follow-up. *Oncotarget*, 2016. 7: 67435.  
<https://www.ncbi.nlm.nih.gov/pubmed/27611947>
87. Roperch, J.P., *et al.* Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer. *BMC Cancer*, 2016. 16: 704.  
<https://www.ncbi.nlm.nih.gov/pubmed/27586786>
88. Ward, D.G., *et al.* Multiplex PCR and Next Generation Sequencing for the Non-Invasive Detection of Bladder Cancer. *PLoS One*, 2016. 11: e0149756.  
<https://www.ncbi.nlm.nih.gov/pubmed/26901314>
89. van der Aa, M.N., *et al.* Microsatellite analysis of voided-urine samples for surveillance of low-grade non-muscle-invasive urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer trial [CEFUB]). *Eur Urol*, 2009. 55: 659.  
<https://www.ncbi.nlm.nih.gov/pubmed/25884545>
90. Roupret, M., *et al.* A comparison of the performance of microsatellite and methylation urine analysis for predicting the recurrence of urothelial cell carcinoma, and definition of a set of markers by Bayesian network analysis. *BJU Int*, 2008. 101: 1448.  
<https://www.ncbi.nlm.nih.gov/pubmed/18325051>
91. Todenhofer, T., *et al.* Prognostic relevance of positive urine markers in patients with negative cystoscopy during surveillance of bladder cancer. *BMC Cancer*, 2015. 15: 155.  
<https://www.ncbi.nlm.nih.gov/pubmed/25884545>
92. Grossman, H.B., *et al.* Detection of bladder cancer using a point-of-care proteomic assay. *JAMA*, 2005. 293: 810.  
<https://www.ncbi.nlm.nih.gov/pubmed/15713770>
93. Kim, P.H., *et al.* Reflex fluorescence *in situ* hybridization assay for suspicious urinary cytology in patients with bladder cancer with negative surveillance cystoscopy. *BJU Int*, 2014. 114: 354.  
<https://www.ncbi.nlm.nih.gov/pubmed/24128299>
94. Starke, N., *et al.* Long-term outcomes in a high-risk bladder cancer screening cohort. *BJU Int*, 2016. 117: 611.  
<https://www.ncbi.nlm.nih.gov/pubmed/25891519>

95. Roobol, M.J., *et al.* Feasibility study of screening for bladder cancer with urinary molecular markers (the BLU-P project). *Urol Oncol*, 2010. 28: 686.  
<https://www.ncbi.nlm.nih.gov/pubmed/21062653>
96. Babjuk, M., *et al.* Urinary cytology and quantitative BTA and UBC tests in surveillance of patients with pT<sub>a</sub>T<sub>1</sub> bladder urothelial carcinoma. *Urology*, 2008. 71: 718.  
<https://www.ncbi.nlm.nih.gov/pubmed/18387400>
97. van der Aa, M.N., *et al.* Cystoscopy revisited as the gold standard for detecting bladder cancer recurrence: diagnostic review bias in the randomized, prospective CEFUB trial. *J Urol*, 2010. 183: 76.  
<https://www.ncbi.nlm.nih.gov/pubmed/19913254>
98. Kurth, K.H., *et al.* Current methods of assessing and treating carcinoma *in situ* of the bladder with or without involvement of the prostatic urethra. *Int J Urol*, 1995. 2 Suppl 2: 8.  
<https://www.ncbi.nlm.nih.gov/pubmed/7553309>
99. Krajewski, W., *et al.* How different cystoscopy methods influence patient sexual satisfaction, anxiety, and depression levels: a randomized prospective trial. *Qual Life Res*, 2017. 26: 625.  
<https://www.ncbi.nlm.nih.gov/pubmed/28050795>
100. Aaronson, D.S., *et al.* Meta-analysis: does lidocaine gel before flexible cystoscopy provide pain relief? *BJU Int*, 2009. 104: 506.  
<https://www.ncbi.nlm.nih.gov/pubmed/19239453>
101. Kramer, M.W., *et al.* Current Evidence of Transurethral En-bloc Resection of Nonmuscle Invasive Bladder Cancer. *Eur Urol Focus*, 2017.  
<https://www.ncbi.nlm.nih.gov/pubmed/28753835>
102. Brausi, M., *et al.* Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage T<sub>a</sub> T<sub>1</sub> transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. *Eur Urol*, 2002. 41: 523.  
<https://www.ncbi.nlm.nih.gov/pubmed/12074794>
103. Richterstetter, M., *et al.* The value of extended transurethral resection of bladder tumour (TURBT) in the treatment of bladder cancer. *BJU Int*, 2012. 110: E76.  
<https://www.ncbi.nlm.nih.gov/pubmed/22313727>
104. Kramer, M.W., *et al.* En bloc resection of urothelium carcinoma of the bladder (EBRUC): a European multicenter study to compare safety, efficacy, and outcome of laser and electrical en bloc transurethral resection of bladder tumor. *World J Urol*, 2015. 33: 1937.  
<https://www.ncbi.nlm.nih.gov/pubmed/25910478>
105. Hurle, R., *et al.* "En Bloc" Resection of Nonmuscle Invasive Bladder Cancer: A Prospective Single-center Study. *Urology*, 2016. 90: 126.  
<https://www.ncbi.nlm.nih.gov/pubmed/26776561>
106. Migliari, R., *et al.* Thulium Laser Endoscopic En Bloc Enucleation of Nonmuscle-Invasive Bladder Cancer. *J Endourol*, 2015. 29: 1258.  
<https://www.ncbi.nlm.nih.gov/pubmed/26102556>
107. Zhang, X.R., *et al.* Two Micrometer Continuous-Wave Thulium Laser Treating Primary Non-Muscle-Invasive Bladder Cancer: Is It Feasible? A Randomized Prospective Study. *Photomed Laser Surg*, 2015. 33: 517.  
<https://www.ncbi.nlm.nih.gov/pubmed/26397029>
108. Mariappan, P., *et al.* Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience. *Eur Urol*, 2010. 57: 843.  
<https://www.ncbi.nlm.nih.gov/pubmed/19524354>
109. Mariappan, P., *et al.* Good quality white-light transurethral resection of bladder tumours (GQ-WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non-muscle-invasive bladder cancer: validation across time and place and recommendation for benchmarking. *BJU Int*, 2012. 109: 1666.  
<https://www.ncbi.nlm.nih.gov/pubmed/22044434>
110. Bolat, D., *et al.* Comparing the short-term outcomes and complications of monopolar and bipolar transurethral resection of non-muscle invasive bladder cancers: a prospective, randomized, controlled study. *Arch Esp Urol*, 2016. 69: 225.  
<https://www.ncbi.nlm.nih.gov/pubmed/27291558>
111. Teoh, J.Y., *et al.* Comparison of Detrusor Muscle Sampling Rate in Monopolar and Bipolar Transurethral Resection of Bladder Tumor: A Randomized Trial. *Ann Surg Oncol*, 2017. 24: 1428.  
<https://www.ncbi.nlm.nih.gov/pubmed/27882470>

112. Venkatramani, V., *et al.* Monopolar versus bipolar transurethral resection of bladder tumors: a single center, parallel arm, randomized, controlled trial. *J Urol*, 2014. 191: 1703.  
<https://www.ncbi.nlm.nih.gov/pubmed/24333244>
113. Sugihara, T., *et al.* Comparison of Perioperative Outcomes including Severe Bladder Injury between Monopolar and Bipolar Transurethral Resection of Bladder Tumors: A Population Based Comparison. *J Urol*, 2014. 192: 1355.  
<https://www.ncbi.nlm.nih.gov/pubmed/24893311>
114. Herr, H.W., *et al.* Management of low grade papillary bladder tumors. *J Urol*, 2007. 178: 1201.  
<https://www.ncbi.nlm.nih.gov/pubmed/17698090>
115. Xu, Y., *et al.* Comparing the treatment outcomes of potassium-titanyl-phosphate laser vaporization and transurethral electroresection for primary nonmuscle-invasive bladder cancer: A prospective, randomized study. *Lasers Surg Med*, 2015. 47: 306.  
<https://www.ncbi.nlm.nih.gov/pubmed/25864416>
116. Picozzi, S.C., *et al.* Is it oncologically safe performing simultaneous transurethral resection of the bladder and prostate? A meta-analysis on 1,234 patients. *Int Urol Nephrol*, 2012. 44: 1325.  
<https://www.ncbi.nlm.nih.gov/pubmed/22710969>
117. Tsivian, A., *et al.* Simultaneous transurethral resection of bladder tumor and benign prostatic hyperplasia: hazardous or a safe timesaver? *J Urol*, 2003. 170: 2241.  
<https://www.ncbi.nlm.nih.gov/pubmed/14634388>
118. van der Meijden, A., *et al.* Significance of bladder biopsies in Ta,T1 bladder tumors: a report from the EORTC Genito-Urinary Tract Cancer Cooperative Group. EORTC-GU Group Superficial Bladder Committee. *Eur Urol*, 1999. 35: 267.  
<https://www.ncbi.nlm.nih.gov/pubmed/10419345>
119. Hara, T., *et al.* Risk of concomitant carcinoma *in situ* determining biopsy candidates among primary non-muscle-invasive bladder cancer patients: retrospective analysis of 173 Japanese cases. *Int J Urol*, 2009. 16: 293.  
<https://www.ncbi.nlm.nih.gov/pubmed/19207607>
120. Palou, J., *et al.* Female gender and carcinoma *in situ* in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guerin. *Eur Urol*, 2012. 62: 118.  
<https://www.ncbi.nlm.nih.gov/pubmed/22101115>
121. Mungan, M.U., *et al.* Risk factors for mucosal prostatic urethral involvement in superficial transitional cell carcinoma of the bladder. *Eur Urol*, 2005. 48: 760.  
<https://www.ncbi.nlm.nih.gov/pubmed/16005563>
122. Huguet, J., *et al.* Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor. *Eur Urol*, 2005. 48: 53.  
<https://www.ncbi.nlm.nih.gov/pubmed/15967252>
123. Kausch, I., *et al.* Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. *Eur Urol*, 2010. 57: 595.  
<https://www.ncbi.nlm.nih.gov/pubmed/20004052>
124. Mowatt, G., *et al.* Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: Systematic review and meta-analysis. *Int J Technol Assess Health Care*, 2011. 27: 3.  
<https://www.ncbi.nlm.nih.gov/pubmed/21262078>
125. Neuzillet, Y., *et al.* Assessment of diagnostic gain with hexaminolevulinate (HAL) in the setting of newly diagnosed non-muscle-invasive bladder cancer with positive results on urine cytology. *Urol Oncol*, 2014. 32: 1135.  
<https://www.ncbi.nlm.nih.gov/pubmed/25023786>
126. Draga, R.O., *et al.* Photodynamic diagnosis (5-aminolevulinic acid) of transitional cell carcinoma after bacillus Calmette-Guerin immunotherapy and mitomycin C intravesical therapy. *Eur Urol*, 2010. 57: 655.  
<https://www.ncbi.nlm.nih.gov/pubmed/19819064>
127. Ray, E.R., *et al.* Hexylaminolaevulinate fluorescence cystoscopy in patients previously treated with intravesical bacille Calmette-Guerin. *BJU Int*, 2010. 105: 789.  
<https://www.ncbi.nlm.nih.gov/pubmed/19832725>
128. Chou, R., *et al.* Comparative Effectiveness of Fluorescent Versus White Light Cystoscopy for Initial Diagnosis or Surveillance of Bladder Cancer on Clinical Outcomes: Systematic Review and Meta-Analysis. *J Urol*, 2017. 197: 548.  
<https://www.ncbi.nlm.nih.gov/pubmed/27780784>

129. Zheng, C., *et al.* Narrow band imaging diagnosis of bladder cancer: systematic review and meta-analysis. *BJU Int*, 2012. 110: E680.  
<https://www.ncbi.nlm.nih.gov/pubmed/22985502>
130. Drejer, D., *et al.* Clinical relevance of narrow-band imaging in flexible cystoscopy: the DaBlaCa-7 study. *Scand J Urol*, 2017. 51: 120.  
<https://www.ncbi.nlm.nih.gov/pubmed/27117749>
131. Ye, Z., *et al.* A comparison of NBI and WLI cystoscopy in detecting non-muscle-invasive bladder cancer: A prospective, randomized and multi-center study. *Sci Rep*, 2015. 5: 10905.  
<https://www.ncbi.nlm.nih.gov/pubmed/26046790>
132. Naito, S., *et al.* The Clinical Research Office of the Endourological Society (CROES) Multicentre Randomised Trial of Narrow Band Imaging-Assisted Transurethral Resection of Bladder Tumour (TURBT) Versus Conventional White Light Imaging-Assisted TURBT in Primary Non-Muscle-invasive Bladder Cancer Patients: Trial Protocol and 1-year Results. *Eur Urol*, 2016. 70: 506.  
<https://www.ncbi.nlm.nih.gov/pubmed/27117749>
133. Grimm, M.O., *et al.* Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. *J Urol*, 2003. 170: 433.  
<https://www.ncbi.nlm.nih.gov/pubmed/12853793>
134. Divrik, R.T., *et al.* The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. *J Urol*, 2006. 175: 1 641.  
<https://www.ncbi.nlm.nih.gov/pubmed/16600720>
135. Lazica, D.A., *et al.* Second transurethral resection after Ta high-grade bladder tumor: a 4.5-year period at a single university center. *Urol Int*, 2014. 92: 131.  
<https://www.ncbi.nlm.nih.gov/pubmed/23988813>
136. Vasdev, N., *et al.* The impact of early re-resection in patients with pT1 high-grade non-muscle invasive bladder cancer. *Ecancermedalscience*, 2012. 6: 269.  
<https://www.ncbi.nlm.nih.gov/pubmed/22988482>
137. Angulo, J.C., *et al.* Second transurethral resection and prognosis of high-grade non-muscle invasive bladder cancer in patients not receiving bacillus Calmette-Guerin. *Actas Urol Esp*, 2014. 38: 164.  
<https://www.ncbi.nlm.nih.gov/pubmed/24613147>
138. Gendy, R., *et al.* Repeat transurethral resection for non-muscle-invasive bladder cancer: a contemporary series. *BJU Int*, 2016. 117 Suppl 4: 54.  
<https://www.ncbi.nlm.nih.gov/pubmed/26486968>
139. Hashine, K., *et al.* Results of second transurethral resection for high-grade T1 bladder cancer. *Urol Ann*, 2016. 8: 10.  
<https://www.ncbi.nlm.nih.gov/pubmed/26834394>
140. El-Barky, E., *et al.* The importance of second-look transurethral resection for superficial bladder cancer. *Journal of Clinical Urology*, 2015. 8: 299.  
<http://journals.sagepub.com/doi/pdf/10.1177/2051415814560189>
141. Dalbagni, G., *et al.* Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer. *Eur Urol*, 2009. 56: 903.  
<https://www.ncbi.nlm.nih.gov/pubmed/19632765>
142. Fritsche, H.M., *et al.* Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. *Eur Urol*, 2010. 57: 300.  
<https://www.ncbi.nlm.nih.gov/pubmed/19766384>
143. Kulkarni, G.S., *et al.* An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. *Eur Urol*, 2010. 57: 60.  
<https://www.ncbi.nlm.nih.gov/pubmed/19740595>
144. Sfakianos, J.P., *et al.* The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Guerin. *J Urol*, 2014. 191: 341.  
<https://www.ncbi.nlm.nih.gov/pubmed/23973518>
145. Bishr, M., *et al.* Tumour stage on re-staging transurethral resection predicts recurrence and progression-free survival of patients with high-risk non-muscle invasive bladder cancer. *Can Urol Assoc J*, 2014. 8: E306.  
<https://www.ncbi.nlm.nih.gov/pubmed/24940455>

146. Gontero, P., *et al.* The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-Guerin. *BJU Int*, 2016. 118: 44.  
<https://www.ncbi.nlm.nih.gov/pubmed/26469362>
147. Naselli, A., *et al.* Role of Restaging Transurethral Resection for T1 Non-muscle invasive Bladder Cancer: A Systematic Review and Meta-analysis. *Eur Urol Focus*, 2017.  
<https://www.ncbi.nlm.nih.gov/pubmed/28753839>
148. Baltaci, S., *et al.* Significance of the interval between first and second transurethral resection on recurrence and progression rates in patients with high-risk non-muscle-invasive bladder cancer treated with maintenance intravesical Bacillus Calmette-Guerin. *BJU Int*, 2015. 116: 721.  
<https://www.ncbi.nlm.nih.gov/pubmed/25715815>
149. Paner, G.P., *et al.* Challenges in Pathologic Staging of Bladder Cancer: Proposals for Fresh Approaches of Assessing Pathologic Stage in Light of Recent Studies and Observations Pertaining to Bladder Histoanatomic Variances. *Adv Anat Pathol*, 2017. 24: 113.  
<https://www.ncbi.nlm.nih.gov/pubmed/28398951>
150. Lopez-Beltran, A., *et al.* Handling and pathology reporting of specimens with carcinoma of the urinary bladder, ureter, and renal pelvis. *Eur Urol*, 2004. 45: 257.  
<https://www.ncbi.nlm.nih.gov/pubmed/15036668>
151. Sylvester, R.J., *et al.* Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. *Eur Urol*, 2006. 49: 466.  
<https://www.ncbi.nlm.nih.gov/pubmed/16442208>
152. Lammers, R.J., *et al.* Prediction model for recurrence probabilities after intravesical chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer, including external validation. *World J Urol*, 2016. 34: 173.  
<https://www.ncbi.nlm.nih.gov/pubmed/26025189>
153. Fernandez-Gomez, J., *et al.* Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. *J Urol*, 2009. 182: 2195.  
<https://www.ncbi.nlm.nih.gov/pubmed/19758621>
154. van Rhijn, B.W., *et al.* Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. *Eur Urol*, 2010. 58: 433.  
<https://www.ncbi.nlm.nih.gov/pubmed/20646825>
155. Fernandez-Gomez, J., *et al.* The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin: external validation of the EORTC risk tables. *Eur Urol*, 2011. 60: 423.  
<https://www.ncbi.nlm.nih.gov/pubmed/21621906>
156. Cambier, S., *et al.* EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guerin. *Eur Urol*, 2016. 69: 60.  
<https://www.ncbi.nlm.nih.gov/pubmed/26210894>
157. Gontero, P., *et al.* Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guerin: results of a retrospective multicenter study of 2451 patients. *Eur Urol*, 2015. 67: 74.  
<https://www.ncbi.nlm.nih.gov/pubmed/25043942>
158. Golijanin, D., *et al.* Carcinoma in a bladder diverticulum: presentation and treatment outcome. *J Urol*, 2003. 170: 1761.  
<https://www.ncbi.nlm.nih.gov/pubmed/14532771>
159. Palou, J., *et al.* Recurrence at three months and high-grade recurrence as prognostic factor of progression in multivariate analysis of T1G2 bladder tumors. *Urology*, 2009. 73: 1313.  
<https://www.ncbi.nlm.nih.gov/pubmed/19362341>
160. Alkhateeb, S.S., *et al.* Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guerin. *Urol Ann*, 2011. 3: 119.  
<https://www.ncbi.nlm.nih.gov/pubmed/21976923>
161. Lamm, D.L. Carcinoma *in situ*. *Urol Clin North Am*, 1992. 19: 499.  
<https://www.ncbi.nlm.nih.gov/pubmed/1636234>



162. Losa, A., *et al.* Low dose bacillus Calmette-Guerin for carcinoma *in situ* of the bladder: long-term results. *J Urol*, 2000. 163: 68.  
<https://www.ncbi.nlm.nih.gov/pubmed/10604316>
163. Griffiths, T.R., *et al.* Treatment of carcinoma *in situ* with intravesical bacillus Calmette-Guerin without maintenance. *J Urol*, 2002. 167: 2408.  
<https://www.ncbi.nlm.nih.gov/pubmed/11992047>
164. Takenaka, A., *et al.* Clinical outcomes of bacillus Calmette-Guerin instillation therapy for carcinoma *in situ* of urinary bladder. *Int J Urol*, 2008. 15: 309.  
<https://www.ncbi.nlm.nih.gov/pubmed/18380817>
165. Solsona, E., *et al.* The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. *J Urol*, 2000. 164: 685.  
<https://www.ncbi.nlm.nih.gov/pubmed/10953125>
166. van Gils-Gielen, R.J., *et al.* Risk factors in carcinoma *in situ* of the urinary bladder. Dutch South East Cooperative Urological Group. *Urology*, 1995. 45: 581.  
<https://www.ncbi.nlm.nih.gov/pubmed/7716838>
167. Lammers, R.J., *et al.* Smoking status is a risk factor for recurrence after transurethral resection of non-muscle-invasive bladder cancer. *Eur Urol*, 2011. 60: 713.  
<https://www.ncbi.nlm.nih.gov/pubmed/21794974>
168. Rink, M., *et al.* Smoking reduces the efficacy of intravesical bacillus Calmette-Guerin immunotherapy in non-muscle-invasive bladder cancer. *Eur Urol*, 2012. 62: 1204.  
<https://www.ncbi.nlm.nih.gov/pubmed/22980442>
169. Rink, M., *et al.* Impact of smoking on outcomes of patients with a history of recurrent nonmuscle invasive bladder cancer. *J Urol*, 2012. 188: 2120.  
<https://www.ncbi.nlm.nih.gov/pubmed/23083868>
170. Crivelli, J.J., *et al.* Effect of smoking on outcomes of urothelial carcinoma: a systematic review of the literature. *Eur Urol*, 2014. 65: 742.  
<https://www.ncbi.nlm.nih.gov/pubmed/23810104>
171. Grotenhuis, A.J., *et al.* The effect of smoking and timing of smoking cessation on clinical outcome in non-muscle-invasive bladder cancer. *Urol Oncol*, 2015. 33: 65 e9.  
<https://www.ncbi.nlm.nih.gov/pubmed/23810104>
172. Muller, J., *et al.* Trends in the risk of second primary cancer among bladder cancer survivors: a population-based cohort of 10 047 patients. *BJU Int*, 2016. 118: 53.  
<https://www.ncbi.nlm.nih.gov/pubmed/26469096>
173. Soloway, M.S., *et al.* Urothelial susceptibility to tumor cell implantation: influence of cauterization. *Cancer*, 1980. 46: 1158.  
<https://www.ncbi.nlm.nih.gov/pubmed/7214299>
174. Pan, J.S., *et al.* Inhibition of implantation of murine bladder tumor by thiotepa in cauterized bladder. *J Urol*, 1989. 142: 1589.  
<https://www.ncbi.nlm.nih.gov/pubmed/2511340>
175. Brocks, C.P., *et al.* Inhibition of tumor implantation by intravesical gemcitabine in a murine model of superficial bladder cancer. *J Urol*, 2005. 174: 1115.  
<https://www.ncbi.nlm.nih.gov/pubmed/16094076>
176. Oosterlinck, W., *et al.* A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. *J Urol*, 1993. 149: 749.  
<https://www.ncbi.nlm.nih.gov/pubmed/8455236>
177. Sylvester, R.J., *et al.* Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation? *Eur Urol*, 2016. 69: 231.  
<https://www.ncbi.nlm.nih.gov/pubmed/26091833>
178. Sylvester, R.J., *et al.* A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. *J Urol*, 2004. 171: 2186.  
<https://www.ncbi.nlm.nih.gov/pubmed/15126782>
179. Abern, M.R., *et al.* Perioperative intravesical chemotherapy in non-muscle-invasive bladder cancer: a systematic review and meta-analysis. *J Natl Compr Canc Netw*, 2013. 11: 477.  
<https://www.ncbi.nlm.nih.gov/pubmed/23584348>

180. Perlis, N., *et al.* Immediate post-transurethral resection of bladder tumor intravesical chemotherapy prevents non-muscle-invasive bladder cancer recurrences: an updated meta-analysis on 2548 patients and quality-of-evidence review. *Eur Urol*, 2013. 64: 421.  
<https://www.ncbi.nlm.nih.gov/pubmed/23830475>
181. Pode, D., *et al.* The mechanism of human bladder tumor implantation in an in vitro model. *J Urol*, 1986. 136: 482.  
<https://www.ncbi.nlm.nih.gov/pubmed/3525861>
182. Bohle, A., *et al.* Inhibition of bladder carcinoma cell adhesion by oligopeptide combinations in vitro and in vivo. *J Urol*, 2002. 167: 357.  
<https://www.ncbi.nlm.nih.gov/pubmed/11743356>
183. Oddens, J.R., *et al.* One immediate postoperative instillation of chemotherapy in low risk Ta, T1 bladder cancer patients. Is it always safe? *Eur Urol*, 2004. 46: 336.  
<https://www.ncbi.nlm.nih.gov/pubmed/15306104>
184. Elmamoun, M.H., *et al.* Destruction of the bladder by single dose Mitomycin C for low-stage transitional cell carcinoma (TCC)--avoidance, recognition, management and consent. *BJU Int*, 2014. 113: E34.  
<https://www.ncbi.nlm.nih.gov/pubmed/24053461>
185. Tolley, D.A., *et al.* The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. *J Urol*, 1996. 155: 1233.  
<https://www.ncbi.nlm.nih.gov/pubmed/8632538>
186. Huncharek, M., *et al.* Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis. *Anticancer Res*, 2001. 21: 765.  
<https://www.ncbi.nlm.nih.gov/pubmed/11299841>
187. Bohle, A., *et al.* Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. *Urology*, 2004. 63: 682.  
<https://www.ncbi.nlm.nih.gov/pubmed/15072879>
188. Sylvester, R.J., *et al.* Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. *J Urol*, 2002. 168: 1964.  
<https://www.ncbi.nlm.nih.gov/pubmed/12394686>
189. Malmstrom, P.U., *et al.* An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. *Eur Urol*, 2009. 56: 247.  
<https://www.ncbi.nlm.nih.gov/pubmed/19409692>
190. Sylvester, R.J., *et al.* Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. *Eur Urol*, 2010. 57: 766.  
<https://www.ncbi.nlm.nih.gov/pubmed/20034729>
191. Shang, P.F., *et al.* Intravesical Bacillus Calmette-Guerin versus epirubicin for Ta and T1 bladder cancer. *Cochrane Database Syst Rev*, 2011: CD006885.  
<https://www.ncbi.nlm.nih.gov/pubmed/21563157>
192. Bosschieter, J., *et al.* Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients. *Eur Urol*, 2017.  
<https://www.ncbi.nlm.nih.gov/pubmed/28705539>
193. Bouffieux, C., *et al.* Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. *European Organization for Research and Treatment of Cancer Genitourinary Group. J Urol*, 1995. 153: 934.  
<https://www.ncbi.nlm.nih.gov/pubmed/7853578>
194. Kaasinen, E., *et al.* Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma. *Eur Urol*, 2002. 42: 167.  
<https://www.ncbi.nlm.nih.gov/pubmed/12160589>
195. Sylvester, R.J., *et al.* The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials. *Eur Urol*, 2008. 53: 709.  
<https://www.ncbi.nlm.nih.gov/pubmed/18207317>

196. Au, J.L., *et al.* Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. *J Natl Cancer Inst*, 2001. 93: 597.  
<https://www.ncbi.nlm.nih.gov/pubmed/11309436>
197. Giesbers, A.A., *et al.* Recurrence of superficial bladder carcinoma after intravesical instillation of mitomycin-C. Comparison of exposure times. *Br J Urol*, 1989. 63: 176.  
<https://www.ncbi.nlm.nih.gov/pubmed/2495144>
198. Kuroda, M., *et al.* Effect of prophylactic treatment with intravesical epirubicin on recurrence of superficial bladder cancer--The 6th Trial of the Japanese Urological Cancer Research Group (JUCRG): a randomized trial of intravesical epirubicin at dose of 20mg/40ml, 30mg/40ml, 40mg/40ml. *Eur Urol*, 2004. 45: 600.  
<https://www.ncbi.nlm.nih.gov/pubmed/15082202>
199. Arends, T.J., *et al.* Combined chemohyperthermia: 10-year single center experience in 160 patients with nonmuscle invasive bladder cancer. *J Urol*, 2014. 192: 708.  
<https://www.ncbi.nlm.nih.gov/pubmed/24704017>
200. Arends, T.J., *et al.* Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guerin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer. *Eur Urol*, 2016. 69: 1046.  
<https://www.ncbi.nlm.nih.gov/pubmed/26803476>
201. Di Stasi, S.M., *et al.* Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. *Lancet Oncol*, 2006. 7: 43.  
<https://www.ncbi.nlm.nih.gov/pubmed/16389183>
202. Shelley, M.D., *et al.* A systematic review of intravesical bacillus Calmette-Guerin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. *BJU Int*, 2001. 88: 209.  
<https://www.ncbi.nlm.nih.gov/pubmed/11488731>
203. Han, R.F., *et al.* Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. *Urology*, 2006. 67: 1216.  
<https://www.ncbi.nlm.nih.gov/pubmed/16765182>
204. Shelley, M.D., *et al.* Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. *BJU Int*, 2004. 93: 485.  
<https://www.ncbi.nlm.nih.gov/pubmed/15008714>
205. Bohle, A., *et al.* Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. *J Urol*, 2003. 169: 90.  
<https://www.ncbi.nlm.nih.gov/pubmed/12478111>
206. Duchek, M., *et al.* Bacillus Calmette-Guerin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study. *Eur Urol*, 2010. 57: 25.  
<https://www.ncbi.nlm.nih.gov/pubmed/19819617>
207. Jarvinen, R., *et al.* Long-term efficacy of maintenance bacillus Calmette-Guerin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma *in situ*: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up. *Eur Urol*, 2009. 56: 260.  
<https://www.ncbi.nlm.nih.gov/pubmed/19395154>
208. Huncharek, M., *et al.* The influence of intravesical therapy on progression of superficial transitional cell carcinoma of the bladder: a metaanalytic comparison of chemotherapy versus bacilli Calmette-Guerin immunotherapy. *Am J Clin Oncol*, 2004. 27: 522.  
<https://www.ncbi.nlm.nih.gov/pubmed/15596924>
209. Oddens, J.R., *et al.* The effect of age on the efficacy of maintenance bacillus calmette-guerin relative to maintenance epirubicin in patients with stage ta t1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911. *Eur Urol*, 2014. 66: 694.  
<https://www.ncbi.nlm.nih.gov/pubmed/24948466>
210. Rentsch, C.A., *et al.* Bacillus calmette-guerin strain differences have an impact on clinical outcome in bladder cancer immunotherapy. *Eur Urol*, 2014. 66: 677.  
<https://www.ncbi.nlm.nih.gov/pubmed/24674149>
211. Sengiku, A., *et al.* A prospective comparative study of intravesical bacillus Calmette-Guerin therapy with the Tokyo or Connaught strain for nonmuscle invasive bladder cancer. *J Urol*, 2013. 190: 50.  
<https://www.ncbi.nlm.nih.gov/pubmed/23376145>

212. van der Meijden, A.P., *et al.* Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. *Eur Urol*, 2003. 44: 429.  
<https://www.ncbi.nlm.nih.gov/pubmed/14499676>
213. Brausi, M., *et al.* Side effects of Bacillus Calmette-Guerin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. *Eur Urol*, 2014. 65: 69.  
<https://www.ncbi.nlm.nih.gov/pubmed/23910233>
214. Oddens, J.R., *et al.* Increasing age is not associated with toxicity leading to discontinuation of treatment in patients with urothelial non-muscle-invasive bladder cancer randomised to receive 3 years of maintenance bacille Calmette-Guerin: results from European Organisation for Research and Treatment of Cancer Genito-Urinary Group study 30911. *BJU Int*, 2016. 118: 423.  
<https://www.ncbi.nlm.nih.gov/pubmed/26945890>
215. Herr, H.W. Intravesical bacillus Calmette-Guerin outcomes in patients with bladder cancer and asymptomatic bacteriuria. *J Urol*, 2012. 187: 435.  
<https://www.ncbi.nlm.nih.gov/pubmed/22177154>
216. Herr, H.W. Outpatient urological procedures in antibiotic-naive patients with bladder cancer with asymptomatic bacteriuria. *BJU Int*, 2012. 110: E658.  
<https://www.ncbi.nlm.nih.gov/pubmed/22883017>
217. Lamm, D.L., *et al.* Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. *J Urol*, 1992. 147: 596.  
<https://www.ncbi.nlm.nih.gov/pubmed/1538436>
218. Palou, J., *et al.* Intravesical bacillus Calmette-Guerin for the treatment of superficial bladder cancer in renal transplant patients. *Transplantation*, 2003. 76: 1514.  
<https://www.ncbi.nlm.nih.gov/pubmed/14657696>
219. Yossepowitch, O., *et al.* Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients. *J Urol*, 2006. 176: 482.  
<https://www.ncbi.nlm.nih.gov/pubmed/16813873>
220. Roumeguere, T., *et al.* Bacillus Calmette-Guerin therapy in non-muscle-invasive bladder carcinoma after renal transplantation for end-stage aristolochic acid nephropathy. *Transpl Int*, 2015. 28: 199.  
<https://www.ncbi.nlm.nih.gov/pubmed/25377421>
221. Rodriguez, F., *et al.* [Practical guideline for the management of adverse events associated with BCG installations]. *Arch Esp Urol*, 2008. 61: 591.  
<https://www.ncbi.nlm.nih.gov/pubmed/18709813>
222. Witjes, J.A., *et al.* Clinical practice recommendations for the prevention and management of intravesical therapy-associated adverse events. *Eur Urol Suppl*, 2008. 7: 667.  
[http://www.europeanurology.com/article/S1569-9056\(08\)00110-3/abstract](http://www.europeanurology.com/article/S1569-9056(08)00110-3/abstract)
223. Palou, J., *et al.* Intravesical treatment of severe bacillus Calmette-Guerin cystitis. *Int Urol Nephrol*, 2001. 33: 485.  
<https://www.ncbi.nlm.nih.gov/pubmed/12230277>
224. Falkensammer, C., *et al.* Late occurrence of bilateral tuberculous-like epididymo-orchitis after intravesical bacille Calmette-Guerin therapy for superficial bladder carcinoma. *Urology*, 2005. 65: 175.  
<https://www.ncbi.nlm.nih.gov/pubmed/15667898>
225. Tinazzi, E., *et al.* Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review. *Rheumatol Int*, 2006. 26: 481.  
<https://www.ncbi.nlm.nih.gov/pubmed/16220289>
226. Morales, A., *et al.* Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. *J Urol*, 1976. 116: 180.  
<https://www.ncbi.nlm.nih.gov/pubmed/820877>
227. Lamm, D.L., *et al.* Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma *in situ* transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. *J Urol*, 2000. 163: 1124.  
<https://www.ncbi.nlm.nih.gov/pubmed/10737480>
228. Zlotta, A.R., *et al.* What is the optimal regimen for BCG intravesical therapy? Are six weekly instillations necessary? *Eur Urol*, 2000. 37: 470.  
<https://www.ncbi.nlm.nih.gov/pubmed/10765079>

229. Oddens, J., *et al.* Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guerin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. *Eur Urol*, 2013. 63: 462.  
<https://www.ncbi.nlm.nih.gov/pubmed/23141049>
230. Martinez-Pineiro, L., *et al.* Maintenance Therapy with 3-monthly Bacillus Calmette-Guerin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013. *Eur Urol*, 2015. 68: 256.  
<https://www.ncbi.nlm.nih.gov/pubmed/25794457>
231. Martinez-Pineiro, J.A., *et al.* Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27 mg in superficial bladder cancer. *BJU Int*, 2002. 89: 671.  
<https://www.ncbi.nlm.nih.gov/pubmed/11966623>
232. Martinez-Pineiro, J.A., *et al.* Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. *J Urol*, 2005. 174: 1242.  
<https://www.ncbi.nlm.nih.gov/pubmed/16145378>
233. Ojea, A., *et al.* A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C. *Eur Urol*, 2007. 52: 1398.  
<https://www.ncbi.nlm.nih.gov/pubmed/17485161>
234. Solsona, E., *et al.* Sequential combination of mitomycin C plus bacillus Calmette-Guerin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomized prospective trial. *Eur Urol*, 2015. 67: 508.  
<https://www.ncbi.nlm.nih.gov/pubmed/25301758>
235. Shepherd, A.R., *et al.* Intravesical Bacillus Calmette-Guerin with interferon-alpha versus intravesical Bacillus Calmette-Guerin for treating non-muscle-invasive bladder cancer. *Cochrane Database Syst Rev*, 2017. 3: CD012112.  
<https://www.ncbi.nlm.nih.gov/pubmed/28268259>
236. Marttila, T., *et al.* Intravesical Bacillus Calmette-Guerin Versus Combination of Epirubicin and Interferon-alpha2a in Reducing Recurrence of Non-Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study. *Eur Urol*, 2016. 70: 341.  
<https://www.ncbi.nlm.nih.gov/pubmed/27085624>
237. Cui, J., *et al.* Combination of Intravesical Chemotherapy and Bacillus Calmette-Guerin Versus Bacillus Calmette-Guerin Monotherapy in Intermediate- and High-risk Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-analysis. *Medicine (Baltimore)*, 2016. 95: e2572.  
<https://www.ncbi.nlm.nih.gov/pubmed/26817914>
238. Jakse, G., *et al.* Intravesical BCG in patients with carcinoma *in situ* of the urinary bladder: long-term results of EORTC GU Group phase II protocol 30861. *Eur Urol*, 2001. 40: 144.  
<https://www.ncbi.nlm.nih.gov/pubmed/11528191>
239. Gofrit, O.N., *et al.* The natural history of bladder carcinoma *in situ* after initial response to bacillus Calmette-Guerin immunotherapy. *Urol Oncol*, 2009. 27: 258.  
<https://www.ncbi.nlm.nih.gov/pubmed/18440839>
240. Sylvester, R.J., *et al.* Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma *in situ* of the bladder: a meta-analysis of the published results of randomized clinical trials. *J Urol*, 2005. 174: 86.  
<https://www.ncbi.nlm.nih.gov/pubmed/>
241. Kaasinen, E., *et al.* Seventeen-year follow-up of the prospective randomized Nordic CIS study: BCG monotherapy versus alternating therapy with mitomycin C and BCG in patients with carcinoma *in situ* of the urinary bladder. *Scand J Urol*, 2016. 50: 360.  
<https://www.ncbi.nlm.nih.gov/pubmed/27603424>
242. Solsona, E., *et al.* Extravesical involvement in patients with bladder carcinoma *in situ*: biological and therapy implications. *J Urol*, 1996. 155: 895.  
<https://www.ncbi.nlm.nih.gov/pubmed/8583601>
243. Palou, J., *et al.* Urothelial carcinoma of the prostate. *Urology*, 2007. 69: 50.  
<https://www.ncbi.nlm.nih.gov/pubmed/17280908>

244. Palou Redorta, J., *et al.* Intravesical instillations with bacillus calmette-guerin for the treatment of carcinoma *in situ* involving prostatic ducts. *Eur Urol*, 2006. 49: 834.  
<https://www.ncbi.nlm.nih.gov/pubmed/16426729>
245. Herr, H.W., *et al.* Defining bacillus Calmette-Guerin refractory superficial bladder tumors. *J Urol*, 2003. 169: 1706.  
<https://www.ncbi.nlm.nih.gov/pubmed/12686813>
246. Lerner, S.P., *et al.* Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer. *Urol Oncol*, 2009. 27: 155.  
<https://www.ncbi.nlm.nih.gov/pubmed/18367117>
247. van den Bosch, S., *et al.* Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review. *Eur Urol*, 2011. 60: 493.  
<https://www.ncbi.nlm.nih.gov/pubmed/21664041>
248. Gallagher, B.L., *et al.* Impact of previous bacille Calmette-Guerin failure pattern on subsequent response to bacille Calmette-Guerin plus interferon intravesical therapy. *Urology*, 2008. 71: 297.  
<https://www.ncbi.nlm.nih.gov/pubmed/18308107>
249. Rosevear, H.M., *et al.* Factors affecting response to bacillus Calmette-Guerin plus interferon for urothelial carcinoma *in situ*. *J Urol*, 2011. 186: 817.  
<https://www.ncbi.nlm.nih.gov/pubmed/21788050>
250. Morales, A., *et al.* Efficacy and safety of MCNA in patients with nonmuscle invasive bladder cancer at high risk for recurrence and progression after failed treatment with bacillus Calmette-Guerin. *J Urol*, 2015. 193: 1135.  
<https://www.ncbi.nlm.nih.gov/pubmed/25286009>
251. Cockerill, P.A., *et al.* Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer. *BJU Int*, 2016. 117: 456.  
<https://www.ncbi.nlm.nih.gov/pubmed/25682834>
252. Dalbagni, G., *et al.* Phase II trial of intravesical gemcitabine in bacille Calmette-Guerin-refractory transitional cell carcinoma of the bladder. *J Clin Oncol*, 2006. 24: 2729.  
<https://www.ncbi.nlm.nih.gov/pubmed/16782913>
253. Barlow, L., *et al.* A single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to bacille Calmette-Guerin therapy. *BJU Int*, 2009. 104: 1098.  
<https://www.ncbi.nlm.nih.gov/pubmed/19389012>
254. Steinberg, G., *et al.* Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma *in situ* of the bladder. The Valrubicin Study Group. *J Urol*, 2000. 163: 761.  
<https://www.ncbi.nlm.nih.gov/pubmed/10687972>
255. Nativ, O., *et al.* Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin. *J Urol*, 2009. 182: 1313.  
<https://www.ncbi.nlm.nih.gov/pubmed/19683278>
256. Joudi, F.N., *et al.* Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. *Urol Oncol*, 2006. 24: 344.  
<https://www.ncbi.nlm.nih.gov/pubmed/16818189>
257. Di Lorenzo, G., *et al.* Gemcitabine versus bacille Calmette-Guerin after initial bacille Calmette-Guerin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial. *Cancer*, 2010. 116: 1893.  
<https://www.ncbi.nlm.nih.gov/pubmed/20162706>
258. Jones, G., *et al.* Intravesical gemcitabine for non-muscle invasive bladder cancer. *Cochrane Database Syst Rev*, 2012. 1: CD009294.  
<https://www.ncbi.nlm.nih.gov/pubmed/22259002>
259. Turker, P., *et al.* Upstaging of urothelial cancer at the time of radical cystectomy: factors associated with upstaging and its effect on outcome. *BJU Int*, 2012. 110: 804.  
<https://www.ncbi.nlm.nih.gov/pubmed/22321341>
260. May, M., *et al.* Pathological upstaging detected in radical cystectomy procedures is associated with a significantly worse tumour-specific survival rate for patients with clinical T1 urothelial carcinoma of the urinary bladder. *Scand J Urol Nephrol*, 2011. 45: 251.  
<https://www.ncbi.nlm.nih.gov/pubmed/21388337>
261. Svatek, R.S., *et al.* Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. *BJU Int*, 2011. 107: 898.  
<https://www.ncbi.nlm.nih.gov/pubmed/21244604>

262. Shariat, S.F., *et al.* Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. *Eur Urol*, 2007. 51: 137.  
<https://www.ncbi.nlm.nih.gov/pubmed/16793197>
263. Moschini, M., *et al.* Comparing long-term outcomes of primary and progressive carcinoma invading bladder muscle after radical cystectomy. *BJU Int*, 2016. 117: 604.  
<https://www.ncbi.nlm.nih.gov/pubmed/25851271>
264. Schrier, B.P., *et al.* Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy. *Eur Urol*, 2004. 45: 292.  
<https://www.ncbi.nlm.nih.gov/pubmed/15036673>
265. Kamat, A.M., *et al.* The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. *J Urol*, 2006. 175: 881.  
<https://www.ncbi.nlm.nih.gov/pubmed/16469571>
266. Raj, G.V., *et al.* Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. *J Urol*, 2007. 177: 1283.  
<https://www.ncbi.nlm.nih.gov/pubmed/17382713>
267. Stein, J.P., *et al.* Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. *J Clin Oncol*, 2001. 19: 666.  
<https://www.ncbi.nlm.nih.gov/pubmed/11157016>
268. Hautmann, R.E., *et al.* Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. *Eur Urol*, 2012. 61: 1039.  
<https://www.ncbi.nlm.nih.gov/pubmed/22381169>
269. Shariat, S.F., *et al.* Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. *J Urol*, 2006. 176: 2414.  
<https://www.ncbi.nlm.nih.gov/pubmed/17085118>
270. Holmang, S., *et al.* Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy. *J Urol*, 2001. 165: 1124.  
<https://www.ncbi.nlm.nih.gov/pubmed/11257652>
271. Gofrit, O.N., *et al.* Watchful waiting policy in recurrent Ta G1 bladder tumors. *Eur Urol*, 2006. 49: 303.  
<https://www.ncbi.nlm.nih.gov/pubmed/16413659>
272. Pruthi, R.S., *et al.* Conservative management of low risk superficial bladder tumors. *J Urol*, 2008. 179: 87.  
<https://www.ncbi.nlm.nih.gov/pubmed/17997444>
273. Hernandez, V., *et al.* Long-term oncological outcomes of an active surveillance program in recurrent low grade Ta bladder cancer. *Urol Oncol*, 2016. 34: 165 e19.  
<https://www.ncbi.nlm.nih.gov/pubmed/26687318>
274. Hurle, R., *et al.* Active surveillance for low-risk non-muscle-invasive bladder cancer: mid-term results from the Bladder cancer Italian Active Surveillance (BIAS) project. *BJU Int*, 2016. 118: 935.  
<https://www.ncbi.nlm.nih.gov/pubmed/27207387>
275. Holmang, S., *et al.* Stage Ta-T1 bladder cancer: the relationship between findings at first followup cystoscopy and subsequent recurrence and progression. *J Urol*, 2002. 167: 1634.  
<https://www.ncbi.nlm.nih.gov/pubmed/11912378>
276. Mariappan, P., *et al.* A surveillance schedule for G1Ta bladder cancer allowing efficient use of check cystoscopy and safe discharge at 5 years based on a 25-year prospective database. *J Urol*, 2005. 173: 1108.  
<https://www.ncbi.nlm.nih.gov/pubmed/15758711>
277. Soukup, V., *et al.* Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature. *Eur Urol*, 2012. 62: 290.  
<https://www.ncbi.nlm.nih.gov/pubmed/22609313>
278. Holmang, S., *et al.* Should follow-up cystoscopy in bacillus Calmette-Guerin-treated patients continue after five tumour-free years? *Eur Urol*, 2012. 61: 503.  
<https://www.ncbi.nlm.nih.gov/pubmed/22119022>
279. Niwa, N., *et al.* Comparison of outcomes between ultrasonography and cystoscopy in the surveillance of patients with initially diagnosed TaG1-2 bladder cancers: A matched-pair analysis. *Urol Oncol*, 2015. 33: 386 e15.  
<https://www.ncbi.nlm.nih.gov/pubmed/26027764>

## 10. CONFLICT OF INTEREST

All members of the Non-Muscle-Invasive Bladder Cancer guidelines working group have provided disclosure statements of all relationships that they have that might be perceived as a potential source of a conflict of interest. This information is publically accessible through the European Association of Urology website: <https://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/?type=panel>.

This guidelines document was developed with the financial support of the European Association of Urology. No external sources of funding and support have been involved. The EAU is a non-profit organisation and funding is limited to administrative assistance and travel and meeting expenses. No honoraria or other reimbursements have been provided.

## 11. CITATION INFORMATION

The format in which to cite the EAU Guidelines will vary depending on the style guide of the journal in which the citation appears. Accordingly, the number of authors or whether, for instance, to include the publisher, location, or an ISBN number may vary.

The compilation of the complete Guidelines should be referenced as:

*EAU Guidelines. Edn. presented at the EAU Annual Congress Copenhagen 2018. ISBN 978-94-92671-01-1.*

If a publisher and/or location is required, include:

*EAU Guidelines Office, Arnhem, The Netherlands. <http://uroweb.org/guidelines/compilations-of-all-guidelines/>*

References to individual guidelines should be structured in the following way:

*Contributors' names. Title of resource. Publication type. ISBN. Publisher and publisher location, year.*